SEC Info - Biolase, Inc - ‘10-Q’ for 3/31/13

SEC Info℠

Home

Help

Please Sign In

Biolase, Inc – ‘10-Q’ for 3/31/13 – ‘EX-101.INS’

On: Friday, 5/10/13, at 4:58pm ET · For: 3/31/13 · Accession #: 1193125-13-214464 · File #: 0-19627

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 5/10/13  Biolase, Inc                      10-Q        3/31/13   61:3.9M                                   Donnelley … Solutions/FA

Quarterly Report — Form 10-Q — Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-Q        Quarterly Report                                    HTML    313K 
 2: EX-31.1     Certification -- §302 - SOA'02                      HTML     24K 
 3: EX-31.2     Certification -- §302 - SOA'02                      HTML     24K 
 4: EX-32.1     Certification -- §906 - SOA'02                      HTML     19K 
 5: EX-32.2     Certification -- §906 - SOA'02                      HTML     19K 
40: R1          Document and Entity Information                     HTML     40K 
30: R2          Consolidated Balance Sheets                         HTML    135K 
38: R3          Consolidated Balance Sheets (Parenthetical)         HTML     47K 
42: R4          Consolidated Statements Of Operations And           HTML    102K 
                Comprehensive Loss                                               
55: R5          Consolidated Statements Of Cash Flows               HTML    128K 
32: R6          Basis of Presentation                               HTML     35K 
37: R7          Recent Accounting Pronouncements                    HTML     27K 
27: R8          Stock-Based Awards and Per Share Information        HTML     60K 
19: R9          Inventory                                           HTML     26K 
57: R10         Property, Plant, and Equipment                      HTML     32K 
44: R11         Intangible Assets and Goodwill                      HTML     46K 
43: R12         Accrued Liabilities and Deferred Revenue            HTML     43K 
48: R13         Lines Of Credit and Other Borrowings                HTML     27K 
49: R14         Commitments and Contingencies                       HTML     30K 
47: R15         Segment Information                                 HTML     32K 
50: R16         Concentrations                                      HTML     21K 
39: R17         Income Taxes                                        HTML     30K 
41: R18         Subsequent Events                                   HTML     24K 
46: R19         Accounting Policies (Policies)                      HTML     89K 
61: R20         Stock-Based Awards and Per Share Information        HTML     59K 
                (Tables)                                                         
52: R21         Inventory (Tables)                                  HTML     24K 
34: R22         Property, Plant, and Equipment (Tables)             HTML     30K 
45: R23         Intangible Assets and Goodwill (Tables)             HTML     40K 
36: R24         Accrued Liabilities and Deferred Revenue (Tables)   HTML     48K 
15: R25         Segment Information (Tables)                        HTML     25K 
53: R26         Basis of Presentation - Additional Information      HTML     44K 
                (Detail)                                                         
58: R27         Stock Based Awards and Per Share Information -      HTML     74K 
                Additional Information (Detail)                                  
23: R28         Classification of Compensation Expense Associated   HTML     27K 
                with Share-Based Payments (Detail)                               
22: R29         Assumptions Used in Estimating Fair Value of Stock  HTML     30K 
                Options Granted (Detail)                                         
25: R30         Summary of Option Activity (Detail)                 HTML     71K 
26: R31         Cash Proceeds Along with Fair Value Disclosures     HTML     37K 
                Related to grants Exercises and Vesting Options                  
                (Detail)                                                         
28: R32         Components of Inventory (Detail)                    HTML     31K 
14: R33         Inventory - Additional Information (Detail)         HTML     24K 
51: R34         Summary of Property, Plant, and Equipment (Detail)  HTML     36K 
33: R35         Property, Plant, and Equipment - Additional         HTML     21K 
                Information (Detail)                                             
35: R36         Intangible Assets and Goodwill - Additional         HTML     22K 
                Information (Detail)                                             
17: R37         Intangible Assets Related to Accumulated            HTML     51K 
                Amortization and Goodwill (Detail)                               
60: R38         Components of Accrued Liabilities (Detail)          HTML     43K 
12: R39         Changes In Initial Product Warranty Accrual and     HTML     37K 
                Expenses Under Initial and Extended Warranties                   
                (Detail)                                                         
29: R40         Summary of Deferred Revenue (Detail)                HTML     37K 
54: R41         Lines of Credit and Other Borrowings - Additional   HTML     66K 
                Information (Detail)                                             
16: R42         Commitments and Contingencies - Additional          HTML     37K 
                Information (Detail)                                             
21: R43         Segment Information - Additional Information        HTML     29K 
                (Detail)                                                         
24: R44         Summary of Net Revenue by Geographic Location       HTML     23K 
                (Detail)                                                         
31: R45         Concentrations - Additional Information (Detail)    HTML     29K 
13: R46         Income Taxes - Additional Information (Detail)      HTML     55K 
18: R47         Subsequent Events - Additional Information          HTML     54K 
                (Detail)                                                         
59: XML         IDEA XML File -- Filing Summary                      XML     90K 
20: EXCEL       IDEA Workbook of Financial Reports (.xls)            XLS    425K 
 6: EX-101.INS  XBRL Instance -- biol-20130331                       XML    711K 
 8: EX-101.CAL  XBRL Calculations -- biol-20130331_cal               XML    159K 
 9: EX-101.DEF  XBRL Definitions -- biol-20130331_def                XML    678K 
10: EX-101.LAB  XBRL Labels -- biol-20130331_lab                     XML    991K 
11: EX-101.PRE  XBRL Presentations -- biol-20130331_pre              XML    767K 
 7: EX-101.SCH  XBRL Schema -- biol-20130331                         XSD    144K 
56: ZIP         XBRL Zipped Folder -- 0001193125-13-214464-xbrl      Zip    114K

‘EX-101.INS’ — XBRL Instance — biol-20130331

This Exhibit is an XBRL XML File.

<?xml version="1.0" standalone="yes" encoding="windows-1252"?>

<xbrll:schemaRef xlink:type="simple" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xlink:href="biol-20130331.xsd" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrll="http://www.xbrl.org/2003/linkbase"/>

<dei:EntityCommonStockSharesOutstanding contextRef="eol_PE753-----1310-Q0003_STD_0_20130503_0" unitRef="shares" decimals="INF" id="id_1838087_A26A8E31-3C00-4AFB-B0C6-A9660AF1F9CA_2_500005"> 31579348 </dei:EntityCommonStockSharesOutstanding>

<us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="eol_PE753-----1310-Q0003_STD_0_20130507_0_506663x511390" unitRef="iso4217_USD" decimals="-5" id="id_1838087_4303F1DD-6AF6-42F3-AA3A-773913C066C6_1002_1"> 10000000 </us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>

<us-gaap:DebtInstrumentBasisSpreadOnVariableRate contextRef="eol_PE753-----1310-Q0003_STD_0_20130507_0_506663x511390_507611x652001" unitRef="pure" decimals="4" id="id_1838087_4F7245D9-9242-4FAE-AF7F-A362379D7F1C_3001_7"> 0.0150 </us-gaap:DebtInstrumentBasisSpreadOnVariableRate>

<biol:LiborFloorRateApplicableToVariableRates contextRef="eol_PE753-----1310-Q0003_STD_0_20130507_0_506663x511390_507611x652001" unitRef="pure" decimals="4" id="id_1838087_4F7245D9-9242-4FAE-AF7F-A362379D7F1C_3001_11"> 0.0250 </biol:LiborFloorRateApplicableToVariableRates>

<us-gaap:DebtInstrumentBasisSpreadOnVariableRate contextRef="eol_PE753-----1310-Q0003_STD_0_20130507_0_506663x511390_507611x652129" unitRef="pure" decimals="4" id="id_1838087_4F7245D9-9242-4FAE-AF7F-A362379D7F1C_4001_6"> 0.0200 </us-gaap:DebtInstrumentBasisSpreadOnVariableRate>

<us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity contextRef="eol_PE753-----1310-Q0003_STD_0_20130507_0_506663x511390_507611x652129" unitRef="iso4217_USD" decimals="-5" id="id_1838087_4F7245D9-9242-4FAE-AF7F-A362379D7F1C_4001_0"> 4000000 </us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity>

<us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="eol_PE753-----1310-Q0003_STD_0_20130507_0_506663x511390_507611x652129" unitRef="iso4217_USD" decimals="-5" id="id_1838087_4F7245D9-9242-4FAE-AF7F-A362379D7F1C_4001_1"> 6000000 </us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>

<biol:LiborFloorRateApplicableToVariableRates contextRef="eol_PE753-----1310-Q0003_STD_0_20130507_0_506663x511390_507611x652129" unitRef="pure" decimals="4" id="id_1838087_4F7245D9-9242-4FAE-AF7F-A362379D7F1C_4001_10"> 0.0250 </biol:LiborFloorRateApplicableToVariableRates>

<biol:RequiredMinimumSharePriceReachedToExerciseWarrants contextRef="eol_PE753-----1310-Q0003_STD_0_20130323_0_504957x513639_509379x517821" unitRef="iso4217_USD_per_shares" decimals="2" id="id_1838087_8C3CCFCF-C27A-4AC2-81F3-7CB8C8BCF0D0_2001_2"> 7.50 </biol:RequiredMinimumSharePriceReachedToExerciseWarrants>

<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="eol_PE753-----1310-Q0003_STD_0_20130323_0_504957x514053_508454x692976_509379x517821" unitRef="shares" decimals="0" id="id_1838087_8C3CCFCF-C27A-4AC2-81F3-7CB8C8BCF0D0_3001_4"> 50000 </us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>

<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="eol_PE753-----1310-Q0003_STD_0_20130323_0_504957x514053_509379x517821" unitRef="shares" decimals="0" id="id_1838087_8C3CCFCF-C27A-4AC2-81F3-7CB8C8BCF0D0_4001_0"> 50000 </us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>

<biol:RequiredMinimumSharePriceReachedToExerciseWarrants contextRef="eol_PE753-----1310-Q0003_STD_0_20130323_0_508454x692976_509379x517821" unitRef="iso4217_USD_per_shares" decimals="2" id="id_1838087_8C3CCFCF-C27A-4AC2-81F3-7CB8C8BCF0D0_5001_5"> 10.00 </biol:RequiredMinimumSharePriceReachedToExerciseWarrants>

<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights contextRef="eol_PE753-----1310-Q0003_STD_0_20130323_0_509379x517821" unitRef="iso4217_USD_per_Unit" decimals="2" id="id_1838087_8C3CCFCF-C27A-4AC2-81F3-7CB8C8BCF0D0_6001_1"> 4.50 </us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>

<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="eol_PE753-----1310-Q0003_STD_0_20130426_0_502116x703647_506663x511390" unitRef="shares" decimals="0" id="id_1838087_2B8A4C6B-74C2-4D69-A95E-F8EBAFF268E5_2001_0"> 500000 </us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>

<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights contextRef="eol_PE753-----1310-Q0003_STD_0_20130426_0_502116x703647_506663x511390" unitRef="iso4217_USD_per_A" decimals="2" id="id_1838087_2B8A4C6B-74C2-4D69-A95E-F8EBAFF268E5_2001_1"> 5.90 </us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>

<us-gaap:ProductWarrantyAccrualClassifiedCurrent contextRef="eol_PE753-----1310-Q0003_STD_0_20120331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_EC213DCE-C2D3-4357-95A0-1D70B1065A3D_1002_5"> 1926000 </us-gaap:ProductWarrantyAccrualClassifiedCurrent>

<us-gaap:ProductWarrantyAccrualNoncurrent contextRef="eol_PE753-----1310-Q0003_STD_0_20120331_0" unitRef="iso4217_USD" xsi:nil="true" id="id_1838087_EC213DCE-C2D3-4357-95A0-1D70B1065A3D_1002_4"/>

<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE753-----1310-Q0003_STD_0_20120331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_4DB91CB0-1518-4BBC-9D34-97A2604088B3_1002_31"> 2772000 </us-gaap:CashAndCashEquivalentsAtCarryingValue>

<us-gaap:StandardProductWarrantyAccrual contextRef="eol_PE753-----1310-Q0003_STD_0_20120331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_EC213DCE-C2D3-4357-95A0-1D70B1065A3D_1002_3"> 1926000 </us-gaap:StandardProductWarrantyAccrual>

<us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="eol_PE753-----1310-Q0003_STD_0_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_7FB09FA3-3C5C-47AA-BEFD-AE7A80B5B370_1_6"> 1637000 </us-gaap:PrepaidExpenseAndOtherAssetsCurrent>

<us-gaap:Goodwill contextRef="eol_PE753-----1310-Q0003_STD_0_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_7FB09FA3-3C5C-47AA-BEFD-AE7A80B5B370_1_10"> 2926000 </us-gaap:Goodwill>

<us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent contextRef="eol_PE753-----1310-Q0003_STD_0_20130331_0" unitRef="iso4217_USD" decimals="0" id="id_1838087_E954D2FD-813F-4E8C-9030-3453C2D2AA98_1_0"> 806000 </us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>

<us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE753-----1310-Q0003_STD_0_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_3C0F75C3-2833-4545-BDA1-5B6358366808_1_6"> 8229000 </us-gaap:PropertyPlantAndEquipmentGross>

<us-gaap:LinesOfCreditCurrent contextRef="eol_PE753-----1310-Q0003_STD_0_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_7FB09FA3-3C5C-47AA-BEFD-AE7A80B5B370_1_16"> 3261000 </us-gaap:LinesOfCreditCurrent>

<us-gaap:AccruedInsuranceCurrent contextRef="eol_PE753-----1310-Q0003_STD_0_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_360F2192-AC96-4B90-A02D-867891357FC1_1_4"> 326000 </us-gaap:AccruedInsuranceCurrent>

<us-gaap:StandardProductWarrantyAccrualCurrent contextRef="eol_PE753-----1310-Q0003_STD_0_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_360F2192-AC96-4B90-A02D-867891357FC1_1_1"> 1755000 </us-gaap:StandardProductWarrantyAccrualCurrent>

<us-gaap:InventoryWorkInProcessNetOfReserves contextRef="eol_PE753-----1310-Q0003_STD_0_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_9CA9C040-5D79-48EB-B387-5851B2A07884_1_1"> 1954000 </us-gaap:InventoryWorkInProcessNetOfReserves>

<us-gaap:ProductWarrantyAccrualClassifiedCurrent contextRef="eol_PE753-----1310-Q0003_STD_0_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_EC213DCE-C2D3-4357-95A0-1D70B1065A3D_1001_5"> 1755000 </us-gaap:ProductWarrantyAccrualClassifiedCurrent>

<us-gaap:OtherAssetsNoncurrent contextRef="eol_PE753-----1310-Q0003_STD_0_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_7FB09FA3-3C5C-47AA-BEFD-AE7A80B5B370_1_12"> 282000 </us-gaap:OtherAssetsNoncurrent>

<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="eol_PE753-----1310-Q0003_STD_0_20130331_0" unitRef="shares" decimals="INF" id="id_1838087_10F7D60D-6A98-40A4-B210-EFAE99262C14_3001_400007"> 2460000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>

<us-gaap:StockholdersEquity contextRef="eol_PE753-----1310-Q0003_STD_0_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_7FB09FA3-3C5C-47AA-BEFD-AE7A80B5B370_1_43"> 9677000 </us-gaap:StockholdersEquity>

<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="eol_PE753-----1310-Q0003_STD_0_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_F82351F1-BC71-4D46-B742-3046E734FE2D_2004_7"> 254000 </us-gaap:FiniteLivedIntangibleAssetsNet>

<us-gaap:InterestPayableCurrentAndNoncurrent contextRef="eol_PE753-----1310-Q0003_STD_0_20130331_0" unitRef="iso4217_USD" decimals="0" id="id_1838087_65E0AFDA-8528-43B0-8417-3ED2204F154C_4001_7"> 18000 </us-gaap:InterestPayableCurrentAndNoncurrent>

<us-gaap:InventoryRawMaterialsNetOfReserves contextRef="eol_PE753-----1310-Q0003_STD_0_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_9CA9C040-5D79-48EB-B387-5851B2A07884_1_0"> 4023000 </us-gaap:InventoryRawMaterialsNetOfReserves>

<us-gaap:CommitmentsAndContingencies contextRef="eol_PE753-----1310-Q0003_STD_0_20130331_0" unitRef="iso4217_USD" xsi:nil="true" id="id_1838087_7FB09FA3-3C5C-47AA-BEFD-AE7A80B5B370_1_25"/>

<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="eol_PE753-----1310-Q0003_STD_0_20130331_0" unitRef="iso4217_USD" decimals="-5" id="id_1838087_053476C4-3EF5-4933-8AA5-88BFA09A7E6B_1001_3"> 2500000 </us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>

<us-gaap:OtherAccruedLiabilitiesCurrent contextRef="eol_PE753-----1310-Q0003_STD_0_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_360F2192-AC96-4B90-A02D-867891357FC1_1_5"> 114000 </us-gaap:OtherAccruedLiabilitiesCurrent>

<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="eol_PE753-----1310-Q0003_STD_0_20130331_0" unitRef="iso4217_USD" decimals="INF" id="id_1838087_A50D0922-0FC2-4C71-A1A6-6ADC46F3675C_1001_3"> 3099000 </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>

<us-gaap:CommonStockSharesAuthorized contextRef="eol_PE753-----1310-Q0003_STD_0_20130331_0" unitRef="shares" decimals="-3" id="id_1838087_7FB09FA3-3C5C-47AA-BEFD-AE7A80B5B370_1_34"> 50000000 </us-gaap:CommonStockSharesAuthorized>

<us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="eol_PE753-----1310-Q0003_STD_0_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_360F2192-AC96-4B90-A02D-867891357FC1_1_0"> 1613000 </us-gaap:EmployeeRelatedLiabilitiesCurrent>

<us-gaap:TreasuryStockShares contextRef="eol_PE753-----1310-Q0003_STD_0_20130331_0" unitRef="shares" decimals="-3" id="id_1838087_7FB09FA3-3C5C-47AA-BEFD-AE7A80B5B370_1_42"> 1964000 </us-gaap:TreasuryStockShares>

<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="eol_PE753-----1310-Q0003_STD_0_20130331_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_1838087_71909E03-642B-4EB8-B21D-D1B644B7C37C_3001_7"> 3.84 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>

<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="eol_PE753-----1310-Q0003_STD_0_20130331_0" unitRef="iso4217_USD" decimals="0" id="id_1838087_A50D0922-0FC2-4C71-A1A6-6ADC46F3675C_1001_2"> 5379000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>

<us-gaap:CommonStockSharesOutstanding contextRef="eol_PE753-----1310-Q0003_STD_0_20130331_0" unitRef="shares" decimals="-3" id="id_1838087_7FB09FA3-3C5C-47AA-BEFD-AE7A80B5B370_1_36"> 31523000 </us-gaap:CommonStockSharesOutstanding>

<us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount contextRef="eol_PE753-----1310-Q0003_STD_0_20130331_0" unitRef="iso4217_USD" decimals="-5" id="id_1838087_AFC9C22A-08F1-4633-9BDA-41A7B4DBF525_1_0"> 12900000 </us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount>

<us-gaap:LineOfCreditFacilityAmountOutstanding contextRef="eol_PE753-----1310-Q0003_STD_0_20130331_0" unitRef="iso4217_USD" decimals="-5" id="id_1838087_5C8075E2-D245-474B-ACBF-767A008061BA_1001_3"> 3300000 </us-gaap:LineOfCreditFacilityAmountOutstanding>

<us-gaap:AccruedProfessionalFeesCurrent contextRef="eol_PE753-----1310-Q0003_STD_0_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_360F2192-AC96-4B90-A02D-867891357FC1_1_3"> 650000 </us-gaap:AccruedProfessionalFeesCurrent>

<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears contextRef="eol_PE753-----1310-Q0003_STD_0_20130331_0" unitRef="iso4217_USD" decimals="0" id="id_1838087_E954D2FD-813F-4E8C-9030-3453C2D2AA98_1_2"> 192000 </us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>

<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears contextRef="eol_PE753-----1310-Q0003_STD_0_20130331_0" unitRef="iso4217_USD" decimals="0" id="id_1838087_E954D2FD-813F-4E8C-9030-3453C2D2AA98_1_1"> 659000 </us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>

<us-gaap:Liabilities contextRef="eol_PE753-----1310-Q0003_STD_0_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_7FB09FA3-3C5C-47AA-BEFD-AE7A80B5B370_1_24"> 20847000 </us-gaap:Liabilities>

<us-gaap:AccountsPayableCurrent contextRef="eol_PE753-----1310-Q0003_STD_0_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_7FB09FA3-3C5C-47AA-BEFD-AE7A80B5B370_1_17"> 8708000 </us-gaap:AccountsPayableCurrent>

<us-gaap:DeferredRevenueCurrent contextRef="eol_PE753-----1310-Q0003_STD_0_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_7FB09FA3-3C5C-47AA-BEFD-AE7A80B5B370_1_20"> 3131000 </us-gaap:DeferredRevenueCurrent>

<us-gaap:OtherLiabilitiesNoncurrent contextRef="eol_PE753-----1310-Q0003_STD_0_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_7FB09FA3-3C5C-47AA-BEFD-AE7A80B5B370_1_23"> 34000 </us-gaap:OtherLiabilitiesNoncurrent>

<us-gaap:PreferredStockSharesAuthorized contextRef="eol_PE753-----1310-Q0003_STD_0_20130331_0" unitRef="shares" decimals="-3" id="id_1838087_7FB09FA3-3C5C-47AA-BEFD-AE7A80B5B370_1_29"> 1000000 </us-gaap:PreferredStockSharesAuthorized>

<us-gaap:DeferredTaxAssetsNetNoncurrent contextRef="eol_PE753-----1310-Q0003_STD_0_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_7FB09FA3-3C5C-47AA-BEFD-AE7A80B5B370_1_11"> 15000 </us-gaap:DeferredTaxAssetsNetNoncurrent>

<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="eol_PE753-----1310-Q0003_STD_0_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_7FB09FA3-3C5C-47AA-BEFD-AE7A80B5B370_1_39"> -114899000 </us-gaap:RetainedEarningsAccumulatedDeficit>

<us-gaap:Assets contextRef="eol_PE753-----1310-Q0003_STD_0_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_7FB09FA3-3C5C-47AA-BEFD-AE7A80B5B370_1_13"> 30524000 </us-gaap:Assets>

<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="eol_PE753-----1310-Q0003_STD_0_20130331_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_1838087_71909E03-642B-4EB8-B21D-D1B644B7C37C_3001_6"> 3.47 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>

<us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="eol_PE753-----1310-Q0003_STD_0_20130331_0" unitRef="iso4217_USD" decimals="-5" id="id_1838087_5C8075E2-D245-474B-ACBF-767A008061BA_1001_1"> 8000000 </us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>

<us-gaap:InventoryValuationReserves contextRef="eol_PE753-----1310-Q0003_STD_0_20130331_0" unitRef="iso4217_USD" decimals="-5" id="id_1838087_1DFFFB05-F4FB-4ED7-8EB9-8B439D98487B_1001_0"> 1900000 </us-gaap:InventoryValuationReserves>

<us-gaap:DeferredTaxLiabilitiesNoncurrent contextRef="eol_PE753-----1310-Q0003_STD_0_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_7FB09FA3-3C5C-47AA-BEFD-AE7A80B5B370_1_22"> 556000 </us-gaap:DeferredTaxLiabilitiesNoncurrent>

<us-gaap:AccountsReceivableNetCurrent contextRef="eol_PE753-----1310-Q0003_STD_0_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_7FB09FA3-3C5C-47AA-BEFD-AE7A80B5B370_1_3"> 10644000 </us-gaap:AccountsReceivableNetCurrent>

<us-gaap:InventoryNet contextRef="eol_PE753-----1310-Q0003_STD_0_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_7FB09FA3-3C5C-47AA-BEFD-AE7A80B5B370_1_5"> 11921000 </us-gaap:InventoryNet>

<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="eol_PE753-----1310-Q0003_STD_0_20130331_0" unitRef="iso4217_USD_per_shares" decimals="3" id="id_1838087_7FB09FA3-3C5C-47AA-BEFD-AE7A80B5B370_1_28"> 0.001 </us-gaap:PreferredStockParOrStatedValuePerShare>

<us-gaap:LiabilitiesAndStockholdersEquity contextRef="eol_PE753-----1310-Q0003_STD_0_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_7FB09FA3-3C5C-47AA-BEFD-AE7A80B5B370_1_44"> 30524000 </us-gaap:LiabilitiesAndStockholdersEquity>

<us-gaap:TreasuryStockValue contextRef="eol_PE753-----1310-Q0003_STD_0_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_7FB09FA3-3C5C-47AA-BEFD-AE7A80B5B370_1_41"> 16399000 </us-gaap:TreasuryStockValue>

<us-gaap:ProductWarrantyAccrualNoncurrent contextRef="eol_PE753-----1310-Q0003_STD_0_20130331_0" unitRef="iso4217_USD" xsi:nil="true" id="id_1838087_EC213DCE-C2D3-4357-95A0-1D70B1065A3D_1001_4"/>

<us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity contextRef="eol_PE753-----1310-Q0003_STD_0_20130331_0" unitRef="iso4217_USD" decimals="-5" id="id_1838087_4E2A4F6E-4575-4C29-B5AF-C6EDEA1716BC_1001_3"> 4700000 </us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity>

<us-gaap:CustomerDepositsCurrent contextRef="eol_PE753-----1310-Q0003_STD_0_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_7FB09FA3-3C5C-47AA-BEFD-AE7A80B5B370_1_19"> 278000 </us-gaap:CustomerDepositsCurrent>

<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE753-----1310-Q0003_STD_0_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_7FB09FA3-3C5C-47AA-BEFD-AE7A80B5B370_1_2"> 1229000 </us-gaap:CashAndCashEquivalentsAtCarryingValue>

<us-gaap:FiniteLivedIntangibleAssetsGross contextRef="eol_PE753-----1310-Q0003_STD_0_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_F82351F1-BC71-4D46-B742-3046E734FE2D_2004_4"> 2800000 </us-gaap:FiniteLivedIntangibleAssetsGross>

<us-gaap:CommonStockSharesIssued contextRef="eol_PE753-----1310-Q0003_STD_0_20130331_0" unitRef="shares" decimals="-3" id="id_1838087_7FB09FA3-3C5C-47AA-BEFD-AE7A80B5B370_1_35"> 33487000 </us-gaap:CommonStockSharesIssued>

<us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal contextRef="eol_PE753-----1310-Q0003_STD_0_20130331_0" unitRef="iso4217_USD" decimals="-5" id="id_1838087_4CD013EE-034E-4E26-A7F7-2E9282E137A7_2001_1"> 45300000 </us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>

<us-gaap:StandardProductWarrantyAccrual contextRef="eol_PE753-----1310-Q0003_STD_0_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_EC213DCE-C2D3-4357-95A0-1D70B1065A3D_1001_3"> 1755000 </us-gaap:StandardProductWarrantyAccrual>

<us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="eol_PE753-----1310-Q0003_STD_0_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_7FB09FA3-3C5C-47AA-BEFD-AE7A80B5B370_1_9"> 254000 </us-gaap:IntangibleAssetsNetExcludingGoodwill>

<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="eol_PE753-----1310-Q0003_STD_0_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_7FB09FA3-3C5C-47AA-BEFD-AE7A80B5B370_1_38"> -376000 </us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>

<us-gaap:AccruedLiabilitiesCurrent contextRef="eol_PE753-----1310-Q0003_STD_0_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_7FB09FA3-3C5C-47AA-BEFD-AE7A80B5B370_1_18"> 4879000 </us-gaap:AccruedLiabilitiesCurrent>

<us-gaap:GoodwillGross contextRef="eol_PE753-----1310-Q0003_STD_0_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_E7B02AA9-ED37-46CC-BFCC-ABD1E4DCFCD9_3001_2"> 2926000 </us-gaap:GoodwillGross>

<us-gaap:LiabilitiesCurrent contextRef="eol_PE753-----1310-Q0003_STD_0_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_7FB09FA3-3C5C-47AA-BEFD-AE7A80B5B370_1_21"> 20257000 </us-gaap:LiabilitiesCurrent>

<us-gaap:DeferredRevenue contextRef="eol_PE753-----1310-Q0003_STD_0_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_A775E125-982E-4646-A43C-5071DEDEC336_1_2"> 3133000 </us-gaap:DeferredRevenue>

<us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="eol_PE753-----1310-Q0003_STD_0_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_7FB09FA3-3C5C-47AA-BEFD-AE7A80B5B370_1_4"> 289000 </us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>

<us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="eol_PE753-----1310-Q0003_STD_0_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_9CA9C040-5D79-48EB-B387-5851B2A07884_1_2"> 5944000 </us-gaap:InventoryFinishedGoodsNetOfReserves>

<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="eol_PE753-----1310-Q0003_STD_0_20130331_0" unitRef="shares" decimals="INF" id="id_1838087_10F7D60D-6A98-40A4-B210-EFAE99262C14_3001_400006"> 4337000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>

<us-gaap:CommonStockValue contextRef="eol_PE753-----1310-Q0003_STD_0_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_7FB09FA3-3C5C-47AA-BEFD-AE7A80B5B370_1_32"> 34000 </us-gaap:CommonStockValue>

<us-gaap:CommonStockParOrStatedValuePerShare contextRef="eol_PE753-----1310-Q0003_STD_0_20130331_0" unitRef="iso4217_USD_per_shares" decimals="3" id="id_1838087_7FB09FA3-3C5C-47AA-BEFD-AE7A80B5B370_1_33"> 0.001 </us-gaap:CommonStockParOrStatedValuePerShare>

<us-gaap:DeferredRevenueNoncurrent contextRef="eol_PE753-----1310-Q0003_STD_0_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_A775E125-982E-4646-A43C-5071DEDEC336_1_5"> 2000 </us-gaap:DeferredRevenueNoncurrent>

<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="eol_PE753-----1310-Q0003_STD_0_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_F82351F1-BC71-4D46-B742-3046E734FE2D_2004_5"> 2546000 </us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>

<us-gaap:AssetsCurrent contextRef="eol_PE753-----1310-Q0003_STD_0_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_7FB09FA3-3C5C-47AA-BEFD-AE7A80B5B370_1_7"> 25431000 </us-gaap:AssetsCurrent>

<us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic contextRef="eol_PE753-----1310-Q0003_STD_0_20130331_0" unitRef="iso4217_USD" decimals="-5" id="id_1838087_4CD013EE-034E-4E26-A7F7-2E9282E137A7_2001_0"> 69500000 </us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>

<us-gaap:PreferredStockSharesOutstanding contextRef="eol_PE753-----1310-Q0003_STD_0_20130331_0" unitRef="shares" decimals="-3" id="id_1838087_7FB09FA3-3C5C-47AA-BEFD-AE7A80B5B370_1_31"> 0 </us-gaap:PreferredStockSharesOutstanding>

<us-gaap:PreferredStockSharesIssued contextRef="eol_PE753-----1310-Q0003_STD_0_20130331_0" unitRef="shares" decimals="-3" id="id_1838087_7FB09FA3-3C5C-47AA-BEFD-AE7A80B5B370_1_30"> 0 </us-gaap:PreferredStockSharesIssued>

<us-gaap:PreferredStockValue contextRef="eol_PE753-----1310-Q0003_STD_0_20130331_0" unitRef="iso4217_USD" xsi:nil="true" id="id_1838087_7FB09FA3-3C5C-47AA-BEFD-AE7A80B5B370_1_27"/>

<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="eol_PE753-----1310-Q0003_STD_0_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_3C0F75C3-2833-4545-BDA1-5B6358366808_1_7"> 6613000 </us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>

<us-gaap:PropertyPlantAndEquipmentNet contextRef="eol_PE753-----1310-Q0003_STD_0_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_7FB09FA3-3C5C-47AA-BEFD-AE7A80B5B370_1_8"> 1616000 </us-gaap:PropertyPlantAndEquipmentNet>

<us-gaap:AdditionalPaidInCapital contextRef="eol_PE753-----1310-Q0003_STD_0_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_7FB09FA3-3C5C-47AA-BEFD-AE7A80B5B370_1_37"> 141317000 </us-gaap:AdditionalPaidInCapital>

<biol:WorkingCapital contextRef="eol_PE753-----1310-Q0003_STD_0_20130331_0" unitRef="iso4217_USD" decimals="-5" id="id_1838087_4E2A4F6E-4575-4C29-B5AF-C6EDEA1716BC_1001_0"> 5200000 </biol:WorkingCapital>

<biol:OperatingLeasesFutureMinimumPaymentsDueInFourYearsAndThereafter contextRef="eol_PE753-----1310-Q0003_STD_0_20130331_0" unitRef="iso4217_USD" decimals="0" id="id_1838087_E954D2FD-813F-4E8C-9030-3453C2D2AA98_1_3"> 0 </biol:OperatingLeasesFutureMinimumPaymentsDueInFourYearsAndThereafter>

<biol:FinancedInsurancePremiumFinanceCharge contextRef="eol_PE753-----1310-Q0003_STD_0_20130331_0" unitRef="pure" decimals="3" id="id_1838087_8441A80E-FB4B-41CE-8297-9A9B7C0AAEEB_1001_2"> 0.030 </biol:FinancedInsurancePremiumFinanceCharge>

<biol:FiniteLivedIntangibleAssetsImpairment contextRef="eol_PE753-----1310-Q0003_STD_0_20130331_0" unitRef="iso4217_USD" xsi:nil="true" id="id_1838087_F82351F1-BC71-4D46-B742-3046E734FE2D_2004_6"/>

<biol:UndeliveredElementsTrainingInstallationAndProductAndSupportServices contextRef="eol_PE753-----1310-Q0003_STD_0_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_A775E125-982E-4646-A43C-5071DEDEC336_1_0"> 1623000 </biol:UndeliveredElementsTrainingInstallationAndProductAndSupportServices>

<biol:StockholdersEquityExcludingTreasuryStock contextRef="eol_PE753-----1310-Q0003_STD_0_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_7FB09FA3-3C5C-47AA-BEFD-AE7A80B5B370_1_40"> 26076000 </biol:StockholdersEquityExcludingTreasuryStock>

<biol:FinancedInsurancePremiumPayable contextRef="eol_PE753-----1310-Q0003_STD_0_20130331_0" unitRef="iso4217_USD" decimals="0" id="id_1838087_8441A80E-FB4B-41CE-8297-9A9B7C0AAEEB_1001_0"> 212000 </biol:FinancedInsurancePremiumPayable>

<biol:UndeliveredElementsExtendedWarrantyCurrent contextRef="eol_PE753-----1310-Q0003_STD_0_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_A775E125-982E-4646-A43C-5071DEDEC336_1_1"> 1510000 </biol:UndeliveredElementsExtendedWarrantyCurrent>

<biol:UndeliveredElementsExtendedWarrantyNoncurrent contextRef="eol_PE753-----1310-Q0003_STD_0_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_A775E125-982E-4646-A43C-5071DEDEC336_1_4"> 2000 </biol:UndeliveredElementsExtendedWarrantyNoncurrent>

<biol:ChangeInControlEmployeeSeverance contextRef="eol_PE753-----1310-Q0003_STD_0_20130331_0" unitRef="iso4217_USD" decimals="0" id="id_1838087_D307BED1-E31A-47D0-9174-5AEF286AA9B6_1_0"> 714000 </biol:ChangeInControlEmployeeSeverance>

<biol:SalesTaxPayableCurrent contextRef="eol_PE753-----1310-Q0003_STD_0_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_360F2192-AC96-4B90-A02D-867891357FC1_1_2"> 421000 </biol:SalesTaxPayableCurrent>

<us-gaap:EntityWideDisclosureOnGeographicAreasLongLivedAssetsInForeignCountries contextRef="eol_PE753-----1310-Q0003_STD_0_20130331_0_501891x531305" unitRef="iso4217_USD" decimals="0" id="id_1838087_5A122A32-A145-48DA-A0F6-39F5C3778270_1001_0"> 397000 </us-gaap:EntityWideDisclosureOnGeographicAreasLongLivedAssetsInForeignCountries>

<biol:StockIssuedDueToWarrantExercise contextRef="eol_PE753-----1310-Q0003_STD_0_20130331_0_507199x551171" unitRef="shares" decimals="INF" id="id_1838087_F422CB74-A961-4DA9-9D0E-AC5F6E7C2C04_2002_3"> 40465 </biol:StockIssuedDueToWarrantExercise>

<us-gaap:LineOfCreditFacilityAmountOutstanding contextRef="eol_PE753-----1310-Q0003_STD_0_20130331_0_507611x652001" unitRef="iso4217_USD" decimals="-5" id="id_1838087_5C8075E2-D245-474B-ACBF-767A008061BA_2001_5"> 1500000 </us-gaap:LineOfCreditFacilityAmountOutstanding>

<biol:LineOfCreditFacilityLiborPlusInterestRate contextRef="eol_PE753-----1310-Q0003_STD_0_20130331_0_507611x652001" unitRef="pure" decimals="4" id="id_1838087_65E0AFDA-8528-43B0-8417-3ED2204F154C_5001_1"> 0.0425 </biol:LineOfCreditFacilityLiborPlusInterestRate>

<biol:LiborFloorRateApplicableToVariableRates contextRef="eol_PE753-----1310-Q0003_STD_0_20130331_0_507611x652001" unitRef="pure" decimals="4" id="id_1838087_65E0AFDA-8528-43B0-8417-3ED2204F154C_5001_3"> 0.0100 </biol:LiborFloorRateApplicableToVariableRates>

<us-gaap:LineOfCreditFacilityAmountOutstanding contextRef="eol_PE753-----1310-Q0003_STD_0_20130331_0_507611x652129" unitRef="iso4217_USD" decimals="-5" id="id_1838087_5C8075E2-D245-474B-ACBF-767A008061BA_3001_4"> 1800000 </us-gaap:LineOfCreditFacilityAmountOutstanding>

<us-gaap:DebtInstrumentInterestRateAtPeriodEnd contextRef="eol_PE753-----1310-Q0003_STD_0_20130331_0_507611x652129" unitRef="pure" decimals="4" id="id_1838087_4F7245D9-9242-4FAE-AF7F-A362379D7F1C_4002_5"> 0.0325 </us-gaap:DebtInstrumentInterestRateAtPeriodEnd>

<biol:LineOfCreditFacilityLiborPlusInterestRate contextRef="eol_PE753-----1310-Q0003_STD_0_20130331_0_507611x652129" unitRef="pure" decimals="4" id="id_1838087_65E0AFDA-8528-43B0-8417-3ED2204F154C_6001_0"> 0.0525 </biol:LineOfCreditFacilityLiborPlusInterestRate>

<biol:LiborFloorRateApplicableToVariableRates contextRef="eol_PE753-----1310-Q0003_STD_0_20130331_0_507611x652129" unitRef="pure" decimals="4" id="id_1838087_65E0AFDA-8528-43B0-8417-3ED2204F154C_6001_2"> 0.0100 </biol:LiborFloorRateApplicableToVariableRates>

<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="eol_PE753-----1310-Q0003_STD_0_20130331_0_508454x652096" unitRef="shares" decimals="INF" id="id_1838087_840B3A50-B002-40D6-BB67-0E5C72706100_1001_3"> 86000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>

<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="eol_PE753-----1310-Q0003_STD_0_20130331_0_508454x652096" unitRef="shares" decimals="INF" id="id_1838087_840B3A50-B002-40D6-BB67-0E5C72706100_1001_0"> 6950000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>

<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="eol_PE753-----1310-Q0003_STD_0_20130331_0_508454x652096" unitRef="shares" decimals="INF" id="id_1838087_840B3A50-B002-40D6-BB67-0E5C72706100_1001_2"> 4337000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>

<biol:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercised contextRef="eol_PE753-----1310-Q0003_STD_0_20130331_0_508454x652096" unitRef="shares" decimals="0" id="id_1838087_840B3A50-B002-40D6-BB67-0E5C72706100_1001_1"> 2527000 </biol:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercised>

<us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="eol_PE753-----1310-Q0003_STD_0_20130331_0_508681x532680" unitRef="iso4217_USD" decimals="0" id="id_1838087_4CD013EE-034E-4E26-A7F7-2E9282E137A7_3001_4"> 516000 </us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>

<us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="eol_PE753-----1310-Q0003_STD_0_20130331_0_508681x532681" unitRef="iso4217_USD" decimals="0" id="id_1838087_4CD013EE-034E-4E26-A7F7-2E9282E137A7_4001_3"> 954000 </us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>

<us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE753-----1310-Q0003_STD_0_20130331_0_510903x498304" unitRef="iso4217_USD" decimals="-3" id="id_1838087_3C0F75C3-2833-4545-BDA1-5B6358366808_1001_2"> 1201000 </us-gaap:PropertyPlantAndEquipmentGross>

<us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE753-----1310-Q0003_STD_0_20130331_0_510903x500372" unitRef="iso4217_USD" decimals="-3" id="id_1838087_3C0F75C3-2833-4545-BDA1-5B6358366808_2001_4"> 1046000 </us-gaap:PropertyPlantAndEquipmentGross>

<us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE753-----1310-Q0003_STD_0_20130331_0_510903x503469" unitRef="iso4217_USD" decimals="-3" id="id_1838087_3C0F75C3-2833-4545-BDA1-5B6358366808_3001_5"> 120000 </us-gaap:PropertyPlantAndEquipmentGross>

<us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE753-----1310-Q0003_STD_0_20130331_0_510903x510947" unitRef="iso4217_USD" decimals="-3" id="id_1838087_3C0F75C3-2833-4545-BDA1-5B6358366808_4001_1"> 238000 </us-gaap:PropertyPlantAndEquipmentGross>

<us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE753-----1310-Q0003_STD_0_20130331_0_510903x512000" unitRef="iso4217_USD" decimals="-3" id="id_1838087_3C0F75C3-2833-4545-BDA1-5B6358366808_5001_0"> 185000 </us-gaap:PropertyPlantAndEquipmentGross>

<us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE753-----1310-Q0003_STD_0_20130331_0_510903x513379" unitRef="iso4217_USD" decimals="-3" id="id_1838087_3C0F75C3-2833-4545-BDA1-5B6358366808_6001_3"> 5439000 </us-gaap:PropertyPlantAndEquipmentGross>

<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="eol_PE753-----1310-Q0003_STD_0_20130331_0_512758x501065" unitRef="iso4217_USD" decimals="-3" id="id_1838087_F82351F1-BC71-4D46-B742-3046E734FE2D_2001_7"> 49000 </us-gaap:FiniteLivedIntangibleAssetsNet>

<us-gaap:FiniteLivedIntangibleAssetsGross contextRef="eol_PE753-----1310-Q0003_STD_0_20130331_0_512758x501065" unitRef="iso4217_USD" decimals="-3" id="id_1838087_F82351F1-BC71-4D46-B742-3046E734FE2D_2001_4"> 1914000 </us-gaap:FiniteLivedIntangibleAssetsGross>

<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="eol_PE753-----1310-Q0003_STD_0_20130331_0_512758x501065" unitRef="iso4217_USD" decimals="-3" id="id_1838087_F82351F1-BC71-4D46-B742-3046E734FE2D_2001_5"> 1865000 </us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>

<biol:FiniteLivedIntangibleAssetsImpairment contextRef="eol_PE753-----1310-Q0003_STD_0_20130331_0_512758x501065" unitRef="iso4217_USD" xsi:nil="true" id="id_1838087_F82351F1-BC71-4D46-B742-3046E734FE2D_2001_6"/>

<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="eol_PE753-----1310-Q0003_STD_0_20130331_0_512758x502477" unitRef="iso4217_USD" decimals="-3" id="id_1838087_F82351F1-BC71-4D46-B742-3046E734FE2D_2003_7"> 205000 </us-gaap:FiniteLivedIntangibleAssetsNet>

<us-gaap:FiniteLivedIntangibleAssetsGross contextRef="eol_PE753-----1310-Q0003_STD_0_20130331_0_512758x502477" unitRef="iso4217_USD" decimals="-3" id="id_1838087_F82351F1-BC71-4D46-B742-3046E734FE2D_2003_4"> 817000 </us-gaap:FiniteLivedIntangibleAssetsGross>

<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="eol_PE753-----1310-Q0003_STD_0_20130331_0_512758x502477" unitRef="iso4217_USD" decimals="-3" id="id_1838087_F82351F1-BC71-4D46-B742-3046E734FE2D_2003_5"> 612000 </us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>

<biol:FiniteLivedIntangibleAssetsImpairment contextRef="eol_PE753-----1310-Q0003_STD_0_20130331_0_512758x502477" unitRef="iso4217_USD" xsi:nil="true" id="id_1838087_F82351F1-BC71-4D46-B742-3046E734FE2D_2003_6"/>

<us-gaap:FiniteLivedIntangibleAssetsGross contextRef="eol_PE753-----1310-Q0003_STD_0_20130331_0_512758x512398" unitRef="iso4217_USD" decimals="-3" id="id_1838087_F82351F1-BC71-4D46-B742-3046E734FE2D_2002_4"> 69000 </us-gaap:FiniteLivedIntangibleAssetsGross>

<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="eol_PE753-----1310-Q0003_STD_0_20130331_0_512758x512398" unitRef="iso4217_USD" decimals="-3" id="id_1838087_F82351F1-BC71-4D46-B742-3046E734FE2D_2002_5"> 69000 </us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>

<biol:FiniteLivedIntangibleAssetsImpairment contextRef="eol_PE753-----1310-Q0003_STD_0_20130331_0_512758x512398" unitRef="iso4217_USD" xsi:nil="true" id="id_1838087_F82351F1-BC71-4D46-B742-3046E734FE2D_2002_6"/>

<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE753-----1310-Q0003_STD_0_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_4DB91CB0-1518-4BBC-9D34-97A2604088B3_2001_30"> 3307000 </us-gaap:CashAndCashEquivalentsAtCarryingValue>

<us-gaap:StandardProductWarrantyAccrual contextRef="eol_PE753-----1310-Q0003_STD_0_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_EC213DCE-C2D3-4357-95A0-1D70B1065A3D_2001_0"> 2218000 </us-gaap:StandardProductWarrantyAccrual>

<us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="eol_PE753-----1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_7FB09FA3-3C5C-47AA-BEFD-AE7A80B5B370_2_6"> 1552000 </us-gaap:PrepaidExpenseAndOtherAssetsCurrent>

<us-gaap:Goodwill contextRef="eol_PE753-----1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_7FB09FA3-3C5C-47AA-BEFD-AE7A80B5B370_2_10"> 2926000 </us-gaap:Goodwill>

<us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE753-----1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_3C0F75C3-2833-4545-BDA1-5B6358366808_2_6"> 8027000 </us-gaap:PropertyPlantAndEquipmentGross>

<us-gaap:LinesOfCreditCurrent contextRef="eol_PE753-----1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_7FB09FA3-3C5C-47AA-BEFD-AE7A80B5B370_2_16"> 1637000 </us-gaap:LinesOfCreditCurrent>

<us-gaap:AccruedInsuranceCurrent contextRef="eol_PE753-----1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_360F2192-AC96-4B90-A02D-867891357FC1_2_4"> 751000 </us-gaap:AccruedInsuranceCurrent>

<us-gaap:StandardProductWarrantyAccrualCurrent contextRef="eol_PE753-----1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_360F2192-AC96-4B90-A02D-867891357FC1_2_1"> 1699000 </us-gaap:StandardProductWarrantyAccrualCurrent>

<us-gaap:InventoryWorkInProcessNetOfReserves contextRef="eol_PE753-----1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_9CA9C040-5D79-48EB-B387-5851B2A07884_2_1"> 1949000 </us-gaap:InventoryWorkInProcessNetOfReserves>

<us-gaap:OtherAssetsNoncurrent contextRef="eol_PE753-----1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_7FB09FA3-3C5C-47AA-BEFD-AE7A80B5B370_2_12"> 305000 </us-gaap:OtherAssetsNoncurrent>

<us-gaap:StockholdersEquity contextRef="eol_PE753-----1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_7FB09FA3-3C5C-47AA-BEFD-AE7A80B5B370_2_43"> 11794000 </us-gaap:StockholdersEquity>

<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="eol_PE753-----1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_F82351F1-BC71-4D46-B742-3046E734FE2D_1004_11"> 300000 </us-gaap:FiniteLivedIntangibleAssetsNet>

<us-gaap:InventoryRawMaterialsNetOfReserves contextRef="eol_PE753-----1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_9CA9C040-5D79-48EB-B387-5851B2A07884_2_0"> 4017000 </us-gaap:InventoryRawMaterialsNetOfReserves>

<us-gaap:CommitmentsAndContingencies contextRef="eol_PE753-----1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" xsi:nil="true" id="id_1838087_7FB09FA3-3C5C-47AA-BEFD-AE7A80B5B370_2_25"/>

<us-gaap:OtherAccruedLiabilitiesCurrent contextRef="eol_PE753-----1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_360F2192-AC96-4B90-A02D-867891357FC1_2_5"> 349000 </us-gaap:OtherAccruedLiabilitiesCurrent>

<us-gaap:CommonStockSharesAuthorized contextRef="eol_PE753-----1310-Q0003_STD_0_20121231_0" unitRef="shares" decimals="-3" id="id_1838087_7FB09FA3-3C5C-47AA-BEFD-AE7A80B5B370_2_34"> 50000000 </us-gaap:CommonStockSharesAuthorized>

<us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="eol_PE753-----1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_360F2192-AC96-4B90-A02D-867891357FC1_2_0"> 2326000 </us-gaap:EmployeeRelatedLiabilitiesCurrent>

<us-gaap:TreasuryStockShares contextRef="eol_PE753-----1310-Q0003_STD_0_20121231_0" unitRef="shares" decimals="-3" id="id_1838087_7FB09FA3-3C5C-47AA-BEFD-AE7A80B5B370_2_42"> 1964000 </us-gaap:TreasuryStockShares>

<us-gaap:CommonStockSharesOutstanding contextRef="eol_PE753-----1310-Q0003_STD_0_20121231_0" unitRef="shares" decimals="-3" id="id_1838087_7FB09FA3-3C5C-47AA-BEFD-AE7A80B5B370_2_36"> 31284000 </us-gaap:CommonStockSharesOutstanding>

<us-gaap:AccruedProfessionalFeesCurrent contextRef="eol_PE753-----1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_360F2192-AC96-4B90-A02D-867891357FC1_2_3"> 502000 </us-gaap:AccruedProfessionalFeesCurrent>

<us-gaap:Liabilities contextRef="eol_PE753-----1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_7FB09FA3-3C5C-47AA-BEFD-AE7A80B5B370_2_24"> 20179000 </us-gaap:Liabilities>

<us-gaap:AccountsPayableCurrent contextRef="eol_PE753-----1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_7FB09FA3-3C5C-47AA-BEFD-AE7A80B5B370_2_17"> 7663000 </us-gaap:AccountsPayableCurrent>

<us-gaap:DeferredRevenueCurrent contextRef="eol_PE753-----1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_7FB09FA3-3C5C-47AA-BEFD-AE7A80B5B370_2_20"> 3226000 </us-gaap:DeferredRevenueCurrent>

<us-gaap:OtherLiabilitiesNoncurrent contextRef="eol_PE753-----1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_7FB09FA3-3C5C-47AA-BEFD-AE7A80B5B370_2_23"> 141000 </us-gaap:OtherLiabilitiesNoncurrent>

<us-gaap:PreferredStockSharesAuthorized contextRef="eol_PE753-----1310-Q0003_STD_0_20121231_0" unitRef="shares" decimals="-3" id="id_1838087_7FB09FA3-3C5C-47AA-BEFD-AE7A80B5B370_2_29"> 1000000 </us-gaap:PreferredStockSharesAuthorized>

<us-gaap:DeferredTaxAssetsNetNoncurrent contextRef="eol_PE753-----1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_7FB09FA3-3C5C-47AA-BEFD-AE7A80B5B370_2_11"> 16000 </us-gaap:DeferredTaxAssetsNetNoncurrent>

<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="eol_PE753-----1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_7FB09FA3-3C5C-47AA-BEFD-AE7A80B5B370_2_39"> -112268000 </us-gaap:RetainedEarningsAccumulatedDeficit>

<us-gaap:Assets contextRef="eol_PE753-----1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_7FB09FA3-3C5C-47AA-BEFD-AE7A80B5B370_2_13"> 31973000 </us-gaap:Assets>

<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="eol_PE753-----1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_1838087_71909E03-642B-4EB8-B21D-D1B644B7C37C_1001_2"> 3.48 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>

<us-gaap:InventoryValuationReserves contextRef="eol_PE753-----1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-5" id="id_1838087_1DFFFB05-F4FB-4ED7-8EB9-8B439D98487B_1002_0"> 1900000 </us-gaap:InventoryValuationReserves>

<us-gaap:DeferredTaxLiabilitiesNoncurrent contextRef="eol_PE753-----1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_7FB09FA3-3C5C-47AA-BEFD-AE7A80B5B370_2_22"> 663000 </us-gaap:DeferredTaxLiabilitiesNoncurrent>

<us-gaap:AccountsReceivableNetCurrent contextRef="eol_PE753-----1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_7FB09FA3-3C5C-47AA-BEFD-AE7A80B5B370_2_3"> 11680000 </us-gaap:AccountsReceivableNetCurrent>

<us-gaap:InventoryNet contextRef="eol_PE753-----1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_7FB09FA3-3C5C-47AA-BEFD-AE7A80B5B370_2_5"> 11142000 </us-gaap:InventoryNet>

<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="eol_PE753-----1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD_per_shares" decimals="3" id="id_1838087_7FB09FA3-3C5C-47AA-BEFD-AE7A80B5B370_2_28"> 0.001 </us-gaap:PreferredStockParOrStatedValuePerShare>

<us-gaap:LiabilitiesAndStockholdersEquity contextRef="eol_PE753-----1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_7FB09FA3-3C5C-47AA-BEFD-AE7A80B5B370_2_44"> 31973000 </us-gaap:LiabilitiesAndStockholdersEquity>

<us-gaap:TreasuryStockValue contextRef="eol_PE753-----1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_7FB09FA3-3C5C-47AA-BEFD-AE7A80B5B370_2_41"> 16399000 </us-gaap:TreasuryStockValue>

<us-gaap:CustomerDepositsCurrent contextRef="eol_PE753-----1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_7FB09FA3-3C5C-47AA-BEFD-AE7A80B5B370_2_19"> 582000 </us-gaap:CustomerDepositsCurrent>

<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE753-----1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_7FB09FA3-3C5C-47AA-BEFD-AE7A80B5B370_2_2"> 2543000 </us-gaap:CashAndCashEquivalentsAtCarryingValue>

<us-gaap:FiniteLivedIntangibleAssetsGross contextRef="eol_PE753-----1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_F82351F1-BC71-4D46-B742-3046E734FE2D_1004_8"> 2800000 </us-gaap:FiniteLivedIntangibleAssetsGross>

<us-gaap:CommonStockSharesIssued contextRef="eol_PE753-----1310-Q0003_STD_0_20121231_0" unitRef="shares" decimals="-3" id="id_1838087_7FB09FA3-3C5C-47AA-BEFD-AE7A80B5B370_2_35"> 33248000 </us-gaap:CommonStockSharesIssued>

<us-gaap:StandardProductWarrantyAccrual contextRef="eol_PE753-----1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_EC213DCE-C2D3-4357-95A0-1D70B1065A3D_3001_0"> 1699000 </us-gaap:StandardProductWarrantyAccrual>

<us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="eol_PE753-----1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_7FB09FA3-3C5C-47AA-BEFD-AE7A80B5B370_2_9"> 300000 </us-gaap:IntangibleAssetsNetExcludingGoodwill>

<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="eol_PE753-----1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_7FB09FA3-3C5C-47AA-BEFD-AE7A80B5B370_2_38"> -320000 </us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>

<us-gaap:AccruedLiabilitiesCurrent contextRef="eol_PE753-----1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_7FB09FA3-3C5C-47AA-BEFD-AE7A80B5B370_2_18"> 6267000 </us-gaap:AccruedLiabilitiesCurrent>

<us-gaap:GoodwillGross contextRef="eol_PE753-----1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_E7B02AA9-ED37-46CC-BFCC-ABD1E4DCFCD9_1001_4"> 2926000 </us-gaap:GoodwillGross>

<us-gaap:LiabilitiesCurrent contextRef="eol_PE753-----1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_7FB09FA3-3C5C-47AA-BEFD-AE7A80B5B370_2_21"> 19375000 </us-gaap:LiabilitiesCurrent>

<us-gaap:DeferredRevenue contextRef="eol_PE753-----1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_A775E125-982E-4646-A43C-5071DEDEC336_2_2"> 3229000 </us-gaap:DeferredRevenue>

<us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="eol_PE753-----1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_7FB09FA3-3C5C-47AA-BEFD-AE7A80B5B370_2_4"> 304000 </us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>

<us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="eol_PE753-----1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_9CA9C040-5D79-48EB-B387-5851B2A07884_2_2"> 5176000 </us-gaap:InventoryFinishedGoodsNetOfReserves>

<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="eol_PE753-----1310-Q0003_STD_0_20121231_0" unitRef="shares" decimals="INF" id="id_1838087_10F7D60D-6A98-40A4-B210-EFAE99262C14_1001_400002"> 3860000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>

<us-gaap:CommonStockValue contextRef="eol_PE753-----1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_7FB09FA3-3C5C-47AA-BEFD-AE7A80B5B370_2_32"> 34000 </us-gaap:CommonStockValue>

<us-gaap:CommonStockParOrStatedValuePerShare contextRef="eol_PE753-----1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD_per_shares" decimals="3" id="id_1838087_7FB09FA3-3C5C-47AA-BEFD-AE7A80B5B370_2_33"> 0.001 </us-gaap:CommonStockParOrStatedValuePerShare>

<us-gaap:DeferredRevenueNoncurrent contextRef="eol_PE753-----1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_A775E125-982E-4646-A43C-5071DEDEC336_2_5"> 3000 </us-gaap:DeferredRevenueNoncurrent>

<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="eol_PE753-----1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_F82351F1-BC71-4D46-B742-3046E734FE2D_1004_9"> 2500000 </us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>

<us-gaap:AssetsCurrent contextRef="eol_PE753-----1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_7FB09FA3-3C5C-47AA-BEFD-AE7A80B5B370_2_7"> 26917000 </us-gaap:AssetsCurrent>

<us-gaap:PreferredStockSharesOutstanding contextRef="eol_PE753-----1310-Q0003_STD_0_20121231_0" unitRef="shares" decimals="-3" id="id_1838087_7FB09FA3-3C5C-47AA-BEFD-AE7A80B5B370_2_31"> 0 </us-gaap:PreferredStockSharesOutstanding>

<us-gaap:PreferredStockSharesIssued contextRef="eol_PE753-----1310-Q0003_STD_0_20121231_0" unitRef="shares" decimals="-3" id="id_1838087_7FB09FA3-3C5C-47AA-BEFD-AE7A80B5B370_2_30"> 0 </us-gaap:PreferredStockSharesIssued>

<us-gaap:PreferredStockValue contextRef="eol_PE753-----1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" xsi:nil="true" id="id_1838087_7FB09FA3-3C5C-47AA-BEFD-AE7A80B5B370_2_27"/>

<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="eol_PE753-----1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_3C0F75C3-2833-4545-BDA1-5B6358366808_2_7"> 6518000 </us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>

<us-gaap:PropertyPlantAndEquipmentNet contextRef="eol_PE753-----1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_7FB09FA3-3C5C-47AA-BEFD-AE7A80B5B370_2_8"> 1509000 </us-gaap:PropertyPlantAndEquipmentNet>

<us-gaap:AdditionalPaidInCapital contextRef="eol_PE753-----1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_7FB09FA3-3C5C-47AA-BEFD-AE7A80B5B370_2_37"> 140747000 </us-gaap:AdditionalPaidInCapital>

<biol:FiniteLivedIntangibleAssetsImpairment contextRef="eol_PE753-----1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" xsi:nil="true" id="id_1838087_F82351F1-BC71-4D46-B742-3046E734FE2D_1004_10"/>

<biol:UndeliveredElementsTrainingInstallationAndProductAndSupportServices contextRef="eol_PE753-----1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_A775E125-982E-4646-A43C-5071DEDEC336_2_0"> 1723000 </biol:UndeliveredElementsTrainingInstallationAndProductAndSupportServices>

<biol:StockholdersEquityExcludingTreasuryStock contextRef="eol_PE753-----1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_7FB09FA3-3C5C-47AA-BEFD-AE7A80B5B370_2_40"> 28193000 </biol:StockholdersEquityExcludingTreasuryStock>

<biol:UndeliveredElementsExtendedWarrantyCurrent contextRef="eol_PE753-----1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_A775E125-982E-4646-A43C-5071DEDEC336_2_1"> 1506000 </biol:UndeliveredElementsExtendedWarrantyCurrent>

<biol:UndeliveredElementsExtendedWarrantyNoncurrent contextRef="eol_PE753-----1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_A775E125-982E-4646-A43C-5071DEDEC336_2_4"> 3000 </biol:UndeliveredElementsExtendedWarrantyNoncurrent>

<biol:SalesTaxPayableCurrent contextRef="eol_PE753-----1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_360F2192-AC96-4B90-A02D-867891357FC1_2_2"> 640000 </biol:SalesTaxPayableCurrent>

<us-gaap:EntityWideDisclosureOnGeographicAreasLongLivedAssetsInForeignCountries contextRef="eol_PE753-----1310-Q0003_STD_0_20121231_0_501891x531305" unitRef="iso4217_USD" decimals="0" id="id_1838087_5A122A32-A145-48DA-A0F6-39F5C3778270_1002_0"> 412000 </us-gaap:EntityWideDisclosureOnGeographicAreasLongLivedAssetsInForeignCountries>

<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="eol_PE753-----1310-Q0003_STD_0_20121231_0_507199x551171" unitRef="shares" decimals="0" id="id_1838087_F422CB74-A961-4DA9-9D0E-AC5F6E7C2C04_2001_0"> 80000 </us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>

<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights contextRef="eol_PE753-----1310-Q0003_STD_0_20121231_0_507199x551171" unitRef="iso4217_USD_per_Right" decimals="2" id="id_1838087_F422CB74-A961-4DA9-9D0E-AC5F6E7C2C04_2001_1"> 2.00 </us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>

<us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="eol_PE753-----1310-Q0003_STD_0_20121231_0_507611x652001" unitRef="iso4217_USD" decimals="-5" id="id_1838087_5C8075E2-D245-474B-ACBF-767A008061BA_2002_2"> 4000000 </us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>

<us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="eol_PE753-----1310-Q0003_STD_0_20121231_0_507611x652129" unitRef="iso4217_USD" decimals="-5" id="id_1838087_5C8075E2-D245-474B-ACBF-767A008061BA_3002_0"> 4000000 </us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>

<us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE753-----1310-Q0003_STD_0_20121231_0_510903x498304" unitRef="iso4217_USD" decimals="-3" id="id_1838087_3C0F75C3-2833-4545-BDA1-5B6358366808_1002_2"> 1193000 </us-gaap:PropertyPlantAndEquipmentGross>

<us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE753-----1310-Q0003_STD_0_20121231_0_510903x500372" unitRef="iso4217_USD" decimals="-3" id="id_1838087_3C0F75C3-2833-4545-BDA1-5B6358366808_2002_4"> 1046000 </us-gaap:PropertyPlantAndEquipmentGross>

<us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE753-----1310-Q0003_STD_0_20121231_0_510903x503469" unitRef="iso4217_USD" decimals="-3" id="id_1838087_3C0F75C3-2833-4545-BDA1-5B6358366808_3002_5"> 132000 </us-gaap:PropertyPlantAndEquipmentGross>

<us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE753-----1310-Q0003_STD_0_20121231_0_510903x510947" unitRef="iso4217_USD" decimals="-3" id="id_1838087_3C0F75C3-2833-4545-BDA1-5B6358366808_4002_1"> 246000 </us-gaap:PropertyPlantAndEquipmentGross>

<us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE753-----1310-Q0003_STD_0_20121231_0_510903x512000" unitRef="iso4217_USD" decimals="-3" id="id_1838087_3C0F75C3-2833-4545-BDA1-5B6358366808_5002_0"> 191000 </us-gaap:PropertyPlantAndEquipmentGross>

<us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE753-----1310-Q0003_STD_0_20121231_0_510903x513379" unitRef="iso4217_USD" decimals="-3" id="id_1838087_3C0F75C3-2833-4545-BDA1-5B6358366808_6002_3"> 5219000 </us-gaap:PropertyPlantAndEquipmentGross>

<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="eol_PE753-----1310-Q0003_STD_0_20121231_0_512758x501065" unitRef="iso4217_USD" decimals="-3" id="id_1838087_F82351F1-BC71-4D46-B742-3046E734FE2D_1001_11"> 81000 </us-gaap:FiniteLivedIntangibleAssetsNet>

<us-gaap:FiniteLivedIntangibleAssetsGross contextRef="eol_PE753-----1310-Q0003_STD_0_20121231_0_512758x501065" unitRef="iso4217_USD" decimals="-3" id="id_1838087_F82351F1-BC71-4D46-B742-3046E734FE2D_1001_8"> 1914000 </us-gaap:FiniteLivedIntangibleAssetsGross>

<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="eol_PE753-----1310-Q0003_STD_0_20121231_0_512758x501065" unitRef="iso4217_USD" decimals="-3" id="id_1838087_F82351F1-BC71-4D46-B742-3046E734FE2D_1001_9"> 1833000 </us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>

<biol:FiniteLivedIntangibleAssetsImpairment contextRef="eol_PE753-----1310-Q0003_STD_0_20121231_0_512758x501065" unitRef="iso4217_USD" xsi:nil="true" id="id_1838087_F82351F1-BC71-4D46-B742-3046E734FE2D_1001_10"/>

<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="eol_PE753-----1310-Q0003_STD_0_20121231_0_512758x502477" unitRef="iso4217_USD" decimals="-3" id="id_1838087_F82351F1-BC71-4D46-B742-3046E734FE2D_1003_11"> 219000 </us-gaap:FiniteLivedIntangibleAssetsNet>

<us-gaap:FiniteLivedIntangibleAssetsGross contextRef="eol_PE753-----1310-Q0003_STD_0_20121231_0_512758x502477" unitRef="iso4217_USD" decimals="-3" id="id_1838087_F82351F1-BC71-4D46-B742-3046E734FE2D_1003_8"> 817000 </us-gaap:FiniteLivedIntangibleAssetsGross>

<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="eol_PE753-----1310-Q0003_STD_0_20121231_0_512758x502477" unitRef="iso4217_USD" decimals="-3" id="id_1838087_F82351F1-BC71-4D46-B742-3046E734FE2D_1003_9"> 598000 </us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>

<biol:FiniteLivedIntangibleAssetsImpairment contextRef="eol_PE753-----1310-Q0003_STD_0_20121231_0_512758x502477" unitRef="iso4217_USD" xsi:nil="true" id="id_1838087_F82351F1-BC71-4D46-B742-3046E734FE2D_1003_10"/>

<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="eol_PE753-----1310-Q0003_STD_0_20121231_0_512758x512398" unitRef="iso4217_USD" xsi:nil="true" id="id_1838087_F82351F1-BC71-4D46-B742-3046E734FE2D_1002_11"/>

<us-gaap:FiniteLivedIntangibleAssetsGross contextRef="eol_PE753-----1310-Q0003_STD_0_20121231_0_512758x512398" unitRef="iso4217_USD" decimals="-3" id="id_1838087_F82351F1-BC71-4D46-B742-3046E734FE2D_1002_8"> 69000 </us-gaap:FiniteLivedIntangibleAssetsGross>

<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="eol_PE753-----1310-Q0003_STD_0_20121231_0_512758x512398" unitRef="iso4217_USD" decimals="-3" id="id_1838087_F82351F1-BC71-4D46-B742-3046E734FE2D_1002_9"> 69000 </us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>

<biol:FiniteLivedIntangibleAssetsImpairment contextRef="eol_PE753-----1310-Q0003_STD_0_20121231_0_512758x512398" unitRef="iso4217_USD" xsi:nil="true" id="id_1838087_F82351F1-BC71-4D46-B742-3046E734FE2D_1002_10"/>

<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate contextRef="eol_PE753-----1310-Q0003_STD_23_20130323_0_509379x517821" id="id_1838087_8C3CCFCF-C27A-4AC2-81F3-7CB8C8BCF0D0_1001_3"> 2018-03-22 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>

<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate contextRef="eol_PE753-----1310-Q0003_STD_34_20130426_0_502116x703647_506663x511390" id="id_1838087_2B8A4C6B-74C2-4D69-A95E-F8EBAFF268E5_1001_3"> 2014-04-24 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>

<biol:ClassOfWarrantOrRightWarrantsExercisable contextRef="eol_PE753-----1310-Q0003_STD_34_20130426_0_502116x703647_506663x511390" unitRef="shares" decimals="0" id="id_1838087_2B8A4C6B-74C2-4D69-A95E-F8EBAFF268E5_1001_2"> 1000 </biol:ClassOfWarrantOrRightWarrantsExercisable>

<biol:EntityWideAccountsReceivableMajorCustomerNumber contextRef="eol_PE753-----1310-Q0003_STD_366_20121231_0" unitRef="Customer" decimals="INF" id="id_1838087_5F4F3C59-2E29-42BC-9096-5BBD3DA1B956_2_0"> 0 </biol:EntityWideAccountsReceivableMajorCustomerNumber>

<biol:InterestRateMarginReduction contextRef="eol_PE753-----1310-Q0003_STD_37_20130507_0_506663x511390_507611x652001" unitRef="pure" decimals="4" id="id_1838087_4F7245D9-9242-4FAE-AF7F-A362379D7F1C_1001_9"> 0.0050 </biol:InterestRateMarginReduction>

<us-gaap:LineOfCreditFacilityCommitmentFeeAmount contextRef="eol_PE753-----1310-Q0003_STD_37_20130507_0_506663x511390_507611x652129" unitRef="iso4217_USD" decimals="0" id="id_1838087_4F7245D9-9242-4FAE-AF7F-A362379D7F1C_2001_3"> 30000 </us-gaap:LineOfCreditFacilityCommitmentFeeAmount>

<us-gaap:LineOfCreditFacilityCommitmentFeePercentage contextRef="eol_PE753-----1310-Q0003_STD_37_20130507_0_506663x511390_507611x652129" unitRef="pure" decimals="3" id="id_1838087_4F7245D9-9242-4FAE-AF7F-A362379D7F1C_2001_2"> 0.015 </us-gaap:LineOfCreditFacilityCommitmentFeePercentage>

<us-gaap:LineOfCreditFacilityIncreaseAdditionalBorrowings contextRef="eol_PE753-----1310-Q0003_STD_37_20130507_0_506663x511390_507611x652129" unitRef="iso4217_USD" decimals="-5" id="id_1838087_4F7245D9-9242-4FAE-AF7F-A362379D7F1C_2001_4"> 2000000 </us-gaap:LineOfCreditFacilityIncreaseAdditionalBorrowings>

<biol:InterestRateMarginReduction contextRef="eol_PE753-----1310-Q0003_STD_37_20130507_0_506663x511390_507611x652129" unitRef="pure" decimals="4" id="id_1838087_4F7245D9-9242-4FAE-AF7F-A362379D7F1C_2001_8"> 0.0100 </biol:InterestRateMarginReduction>

<dei:TradingSymbol contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" id="id_1838087_A26A8E31-3C00-4AFB-B0C6-A9660AF1F9CA_1_400000"> BIOL </dei:TradingSymbol>

<dei:EntityRegistrantName contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" id="id_1838087_A26A8E31-3C00-4AFB-B0C6-A9660AF1F9CA_1_400001"> BIOLASE, INC </dei:EntityRegistrantName>

<dei:AmendmentFlag contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" id="id_1838087_9DAA1C17-B9F7-4683-9C41-30E788904F16_1_1"> false </dei:AmendmentFlag>

<dei:EntityFilerCategory contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" id="id_1838087_A26A8E31-3C00-4AFB-B0C6-A9660AF1F9CA_1_400004"> Accelerated Filer </dei:EntityFilerCategory>

<dei:DocumentFiscalPeriodFocus contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" id="id_1838087_9DAA1C17-B9F7-4683-9C41-30E788904F16_1_4"> Q1 </dei:DocumentFiscalPeriodFocus>

<dei:DocumentFiscalYearFocus contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" id="id_1838087_9DAA1C17-B9F7-4683-9C41-30E788904F16_1_3"> 2013 </dei:DocumentFiscalYearFocus>

<dei:DocumentType contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" id="id_1838087_9DAA1C17-B9F7-4683-9C41-30E788904F16_1_0"> 10-Q </dei:DocumentType>

<dei:DocumentPeriodEndDate contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" id="id_1838087_9DAA1C17-B9F7-4683-9C41-30E788904F16_1_2"> 2013-03-31 </dei:DocumentPeriodEndDate>

<dei:EntityCentralIndexKey contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" id="id_1838087_A26A8E31-3C00-4AFB-B0C6-A9660AF1F9CA_1_400002"> 0000811240 </dei:EntityCentralIndexKey>

<dei:CurrentFiscalYearEndDate contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" id="id_1838087_A26A8E31-3C00-4AFB-B0C6-A9660AF1F9CA_1_400003"> --12-31 </dei:CurrentFiscalYearEndDate>

<us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" id="id_1838087_77426C6E-6422-4043-A048-DEFC82900708_1_0">

<div> Update to Significant Accounting Policies There have been no material changes to the Company’s significant accounting policies which are described in the Company’s 2012 Form 10-K, except as noted below. See Note 2 – Recent Accounting Pronouncements for adoption of updated authoritative guidance. </div>

</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>

<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" unitRef="pure" decimals="4" id="id_1838087_F5FACDCD-D74B-4383-8D73-8F77367ED3F7_1_3"> 0.0080 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>

<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_643BC9AC-CC98-4735-8599-488FD13A80CB_1_2"> 23000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>

<us-gaap:OperatingIncomeLoss contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_A00DA052-212E-4E5F-A7B6-0262EF095DF3_1_11"> -2817000 </us-gaap:OperatingIncomeLoss>

<us-gaap:OtherNoncashIncomeExpense contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_4DB91CB0-1518-4BBC-9D34-97A2604088B3_1_9"> -62000 </us-gaap:OtherNoncashIncomeExpense>

<us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" xsi:nil="true" id="id_1838087_643BC9AC-CC98-4735-8599-488FD13A80CB_1_1"/>

<us-gaap:InventoryPolicyTextBlock contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" id="id_1838087_BEDDE2C3-E966-4AA6-A4BD-52D904D08E08_1_0">

</us-gaap:InventoryPolicyTextBlock>

<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" id="id_1838087_508E2DB3-CE43-45B3-9FE3-A95F6A5B48C6_2001_3"> P3Y7M24D </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>

<us-gaap:StandardProductWarrantyAccrualWarrantiesIssued contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_EC213DCE-C2D3-4357-95A0-1D70B1065A3D_1_1"> 650000 </us-gaap:StandardProductWarrantyAccrualWarrantiesIssued>

<us-gaap:ComprehensiveIncomeNetOfTax contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_A00DA052-212E-4E5F-A7B6-0262EF095DF3_1_20"> -2687000 </us-gaap:ComprehensiveIncomeNetOfTax>

<us-gaap:DepreciationDepletionAndAmortization contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_4DB91CB0-1518-4BBC-9D34-97A2604088B3_1_3"> 145000 </us-gaap:DepreciationDepletionAndAmortization>

<us-gaap:ProceedsFromLinesOfCredit contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_4DB91CB0-1518-4BBC-9D34-97A2604088B3_1_24"> 8350000 </us-gaap:ProceedsFromLinesOfCredit>

<us-gaap:ShareBasedCompensation contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_4DB91CB0-1518-4BBC-9D34-97A2604088B3_1_7"> 368000 </us-gaap:ShareBasedCompensation>

<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_1838087_71909E03-642B-4EB8-B21D-D1B644B7C37C_5001_3"> 3.76 </us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>

<us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" id="id_1838087_4D87B5C1-426C-41F1-872B-47FC9C040E96_1_0">

<div> Net revenue by geographic location based on the location of customers was as follows (in thousands): <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="76%" align="center"> <tr> <td width="80%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="6" align="center">Three Months Ended March 31,</td> <td valign="bottom"> </td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">2013</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">2012</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> United States </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">9,048</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">8,364</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr> <td valign="top"> International </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,549</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,956</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">14,597</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">12,320</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> </tr> </table> </div>

</us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock>

<us-gaap:EarningsPerShareDiluted contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_1838087_A00DA052-212E-4E5F-A7B6-0262EF095DF3_1_23"> -0.08 </us-gaap:EarningsPerShareDiluted>

<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_1838087_71909E03-642B-4EB8-B21D-D1B644B7C37C_5001_5"> 3.68 </us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>

<us-gaap:LiquidityDisclosureTextBlock contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" id="id_1838087_E7590441-9738-45C6-A293-F0DD306C5A72_1_0">

<div> Liquidity and Management’s Plans The Company suffered recurring losses from operations during the three years ended December 31, 2012. Although the Company’s revenues increased during the quarter ended March 31, 2013 compared to the same period in 2012, the Company still incurred a loss from operations and a net loss. At March 31, 2013, the Company had approximately $5.2 million in working capital. The Company’s principal sources of liquidity at March 31, 2013 consisted of approximately $1.2 million in cash and cash equivalents, $10.6 million of net accounts receivable, and $4.7 million of available borrowings under two revolving credit facility agreements. The Company intends to improve its financial condition and ultimately improve its financial results by increasing revenues through expansion of its product offerings and continued development of its direct sales force and distributor relationships both domestically and internationally. Furthermore, to improve liquidity, management amended the Company’s lines of credit increasing the combined aggregate capacity of borrowings to $10.0 million; see Note 13 – Subsequent Events for further discussion. Management expects that the working capital and borrowings available under the lines of credit should be sufficient to fund the requirements of the Company. Management continues to monitor the liquidity of the Company and is prepared to implement cash saving measures in the event that its plans to grow revenue do not materialize in the timeline anticipated by management. </div>

</us-gaap:LiquidityDisclosureTextBlock>

<us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_4DB91CB0-1518-4BBC-9D34-97A2604088B3_1_16"> -659000 </us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>

<us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" id="id_1838087_168F962E-5B4D-4935-A51F-939310F58FF9_1_0">

<div> Newly Adopted Accounting Standards In July 2012, the FASB simplified guidance for testing for impairment of indefinite-lived intangible assets other than goodwill. The changes are intended to reduce compliance costs. The revised guidance allows a qualitative approach for testing indefinite-lived intangible assets for impairment, similar to the recently issued impairment testing guidance for goodwill and allows the option to first assess qualitative factors (events and circumstances) that could have affected the significant inputs used in determining the fair value of the indefinite-lived intangible asset to determine whether it is more likely than not (meaning a likelihood of more than 50 percent) that the indefinite-lived intangible asset is impaired. An organization may choose to bypass the qualitative assessment for any indefinite-lived intangible asset in any period and proceed directly to calculating its fair value. The amendments are effective for annual and interim impairment tests performed for fiscal years beginning after September 15, 2012. The adoption did not have a material impact on the Company’s consolidated financial statements. In February 2013, the FASB issued guidance for reporting of amounts reclassified out of accumulated other comprehensive income. The revised guidance requires reporting the effect of significant reclassifications out of accumulated other comprehensive income on the respective line items in net income if the amount being reclassified is required to be reclassified in its entirety to net income. For other amounts that are not required to be reclassified in their entirety to net income in the same reporting period, an entity is required to cross-reference other disclosures that provide additional detail about these amounts. The amendments do not change the current requirements for reporting net income or other comprehensive income in financial statements. The guidance is effective prospectively for reporting periods beginning after December 15, 2012. The adoption did not have a material impact on the Company’s consolidated financial statements. </div>

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>

<us-gaap:ProvisionForDoubtfulAccounts contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_4DB91CB0-1518-4BBC-9D34-97A2604088B3_1_4"> -11000 </us-gaap:ProvisionForDoubtfulAccounts>

<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" unitRef="shares" decimals="INF" id="id_1838087_10F7D60D-6A98-40A4-B210-EFAE99262C14_5001_400004"> 29000 </us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>

<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" unitRef="shares" xsi:nil="true" id="id_1838087_10F7D60D-6A98-40A4-B210-EFAE99262C14_5001_8"/>

<us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" unitRef="pure" decimals="3" id="id_1838087_F0A3794A-0445-411C-BF60-DBDBBD5B085B_1_1"> 0.049 </us-gaap:EffectiveIncomeTaxRateContinuingOperations>

<us-gaap:ShortTermDebtDescription contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" id="id_1838087_8441A80E-FB4B-41CE-8297-9A9B7C0AAEEB_1_1"> Nine </us-gaap:ShortTermDebtDescription>

<us-gaap:CommitmentsAndContingenciesPolicyTextBlock contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" id="id_1838087_4CDDD60A-5C0F-4C28-BC59-887906F9CDAF_1_0">

<div> The Company discloses material loss contingencies deemed to be reasonably possible and accrues for loss contingencies when, in consultation with its legal advisors, management concludes that a loss is probable and reasonably estimable. The ability to predict the ultimate outcome of such matters involves judgments, estimates, and inherent uncertainties. The actual outcome of such matters could differ materially from management’s estimates. </div>

</us-gaap:CommitmentsAndContingenciesPolicyTextBlock>

<us-gaap:ProceedsFromStockOptionsExercised contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_4DB91CB0-1518-4BBC-9D34-97A2604088B3_1_26"> 76000 </us-gaap:ProceedsFromStockOptionsExercised>

<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_4DB91CB0-1518-4BBC-9D34-97A2604088B3_1_18"> -2822000 </us-gaap:NetCashProvidedByUsedInOperatingActivities>

<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_4DB91CB0-1518-4BBC-9D34-97A2604088B3_1_22"> -149000 </us-gaap:NetCashProvidedByUsedInInvestingActivities>

<us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" id="id_1838087_DEAAD7F3-5A5E-4B28-9048-12F810FFC252_1_0">

<div> Property, plant, and equipment, net is comprised of the following (in thousands): <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="76%" align="center"> <tr> <td width="76%"></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">March 31, 2013</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">December 31, 2012</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Land </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">185</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">191</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr> <td valign="top"> Building </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">238</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">246</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Leasehold improvements </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,201</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,193</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr> <td valign="top"> Equipment and computers </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,439</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,219</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Furniture and fixtures </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,046</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,046</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr> <td valign="top"> Construction in progress </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">120</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">132</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8,229</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8,027</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr> <td valign="top"> Accumulated depreciation and amortization </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(6,613</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(6,518</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Property, plant, and equipment, net </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,616</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,509</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> </tr> </table> </div>

</us-gaap:PropertyPlantAndEquipmentTextBlock>

<us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_4DB91CB0-1518-4BBC-9D34-97A2604088B3_1_17"> -96000 </us-gaap:IncreaseDecreaseInDeferredRevenue>

<us-gaap:IncreaseDecreaseInCustomerDeposits contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_4DB91CB0-1518-4BBC-9D34-97A2604088B3_1_15"> -304000 </us-gaap:IncreaseDecreaseInCustomerDeposits>

<us-gaap:ProductWarrantyExpense contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_EC213DCE-C2D3-4357-95A0-1D70B1065A3D_1_2"> 594000 </us-gaap:ProductWarrantyExpense>

<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_1838087_71909E03-642B-4EB8-B21D-D1B644B7C37C_5001_4"> 2.53 </us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>

<us-gaap:RepaymentsOfLinesOfCredit contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_4DB91CB0-1518-4BBC-9D34-97A2604088B3_1_25"> 6726000 </us-gaap:RepaymentsOfLinesOfCredit>

<us-gaap:AmortizationOfFinancingCosts contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_4DB91CB0-1518-4BBC-9D34-97A2604088B3_1_6"> 38000 </us-gaap:AmortizationOfFinancingCosts>

<us-gaap:InterestExpenseOther contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" decimals="0" id="id_1838087_8441A80E-FB4B-41CE-8297-9A9B7C0AAEEB_1_3"> 2000 </us-gaap:InterestExpenseOther>

<us-gaap:NumberOfOperatingSegments contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" unitRef="Segment" decimals="INF" id="id_1838087_7C7A7929-0872-4EBE-8BE1-8FEC022F0230_1_0"> 1 </us-gaap:NumberOfOperatingSegments>

<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_4DB91CB0-1518-4BBC-9D34-97A2604088B3_1_20"> 139000 </us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>

<us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" id="id_1838087_DB780C2A-8739-433C-8056-5C9BB28ADF3E_1_0">

<div> Inventory is valued at the lower of cost or market (determined by the first-in, first-out method) and is comprised of the following (in thousands): <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="76%" align="center"> <tr> <td width="76%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">March 31, 2013</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">December 31, 2012</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Raw materials </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,023</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,017</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr> <td valign="top"> Work-in-process </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,954</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,949</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Finished goods </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,944</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,176</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> </tr> <tr> <td valign="top"> Inventory, net </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">11,921</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">11,142</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> </tr> </table> </div>

</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>

<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_4DB91CB0-1518-4BBC-9D34-97A2604088B3_1_29"> -1314000 </us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>

<us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_A00DA052-212E-4E5F-A7B6-0262EF095DF3_1_7"> 2247000 </us-gaap:GeneralAndAdministrativeExpense>

<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_4DB91CB0-1518-4BBC-9D34-97A2604088B3_1_14"> -23000 </us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>

<us-gaap:SubsequentEventsTextBlock contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" id="id_1838087_96E13C83-E68D-4063-9726-90BFEC6A0205_1_0">

<div> <p style="TEXT-TRANSFORM: none; MARGIN-TOP: 18px; TEXT-INDENT: 0px; LETTER-SPACING: normal; FONT: medium 'Times New Roman'; WHITE-SPACE: normal; MARGIN-BOTTOM: 0px; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"> NOTE 13—SUBSEQUENT EVENTS <p style="TEXT-TRANSFORM: none; MARGIN-TOP: 6px; TEXT-INDENT: 0px; LETTER-SPACING: normal; FONT: medium 'Times New Roman'; WHITE-SPACE: normal; MARGIN-BOTTOM: 0px; COLOR: rgb(0,0,0); MARGIN-LEFT: 58px; WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"> Lines of Credit <p style="TEXT-TRANSFORM: none; MARGIN-TOP: 6px; TEXT-INDENT: 4%; LETTER-SPACING: normal; FONT: medium 'Times New Roman'; WHITE-SPACE: normal; MARGIN-BOTTOM: 0px; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"> On May 7, 2013, the Company amended the Credit Agreements with Comerica Bank to increase the borrowing capacity under the Domestic Revolver from $4.0 million to $6.0 million, reduce the interest rates, establish certain financial and non-financial covenants, and provide for increased mid-quarter borrowing capacity. The Company paid a one and one-half percent commitment fee of $30,000 for the $2.0 million increase in borrowing capacity under the Domestic Revolver. The interest rates on the outstanding principal balance of the Credit Agreements will bear interest at annual percentage rates equal to the daily prime rate (3.25% at March 31, 2013), plus 2.00% for the Domestic Revolver and 1.50% for the Ex-Im Revolver, a current reduction of 1.00% and 0.50% of the interest rates of the Domestic and Ex-Im Revolvers, respectively. The daily Prime rate is subject to a floor of the daily adjusting LIBOR rate plus 2.50% per annum, or if LIBOR is undeterminable, 2.50% per annum. <p style="TEXT-TRANSFORM: none; MARGIN-TOP: 18px; TEXT-INDENT: 0px; LETTER-SPACING: normal; FONT: medium 'Times New Roman'; WHITE-SPACE: normal; MARGIN-BOTTOM: 0px; COLOR: rgb(0,0,0); MARGIN-LEFT: 58px; WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"> Warrants <p style="TEXT-TRANSFORM: none; MARGIN-TOP: 6px; TEXT-INDENT: 4%; LETTER-SPACING: normal; FONT: medium 'Times New Roman'; WHITE-SPACE: normal; MARGIN-BOTTOM: 0px; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"> Effective May 6, 2013, the Company entered an agreement (the “Affiliation Agreement”) with Sun Dental Laboratories, LLC (“Sun Dental Labs”) as part of business development collaboration to sell 3Shape Corporation’s Trios line of intra-oral scanners. In contemplation of the Affiliation Agreement, and in connection with an initial memorandum of understanding between the parties that preceded the Affiliation Agreement, the Company issued a warrant to Sun Dental Labs (the “Sun Dental Warrant”) on April 26, 2013, to purchase 500,000 shares of common stock at an exercise price of $5.90 per common share. The Sun Dental Warrant is performance-based and will vest at a rate of 1,000 shares for each intra-oral scanner system sold to a customer in conjunction with the Affiliation Agreement. Any unearned and unvested warrant shares will expire on April 24, 2014. Vested warrant shares may be exercised with a cash payment, or, in lieu of a cash payment, Sun Dental Labs may convert the vested warrant shares into a net number of whole common shares. The Company expects to begin recording the effects of the Affiliation Agreement during the three months ending June 30, 2013. </div>

</us-gaap:SubsequentEventsTextBlock>

<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" id="id_1838087_053476C4-3EF5-4933-8AA5-88BFA09A7E6B_1_4"> P1Y3M18D </us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>

<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" unitRef="shares" decimals="-3" id="id_1838087_A00DA052-212E-4E5F-A7B6-0262EF095DF3_1_26"> 31473000 </us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>

<us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" id="id_1838087_054597BD-4BAF-4965-A678-C1CC08C88BB5_1_0">

<div> A summary of option activity under our stock option plans for the three months ended March 31, 2013 is as follows: <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"> <tr> <td width="60%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">Shares</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">Weighted average exercise price</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">Weighted average remaining contractual term (years)</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">Aggregate intrinsic value(1)</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Options outstanding at December 31, 2012 </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,860,000</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3.48</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> Plus: Options granted </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">612,000</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3.76</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Less: Options exercised </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(29,000</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2.53</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> Options forfeited, canceled, or expired </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(106,000</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3.68</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Options outstanding at March 31, 2013 </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,337,000</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3.47</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3.90</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,379,000</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> Options exercisable at March 31, 2013 </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,460,000</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3.84</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3.65</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,099,000</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Vested options expired during the quarter ended March 31, 2013 </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">— </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">— </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> </table> <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td valign="top" width="4%" align="left">(1)</td> <td valign="top" align="left">The intrinsic value calculation does not include negative values. This can occur when the fair market value on the reporting date is less than the exercise price of the grant.</td> </tr> </table> </div>

</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>

<us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" id="id_1838087_137307AB-5950-4022-96E3-2F1FE2333497_1_0">

<div> NOTE 6 – INTANGIBLE ASSETS AND GOODWILL The Company conducted its annual impairment test of intangible assets and goodwill as of June 30, 2012, and determined that there was no impairment. The Company also tests its intangible assets and goodwill between the annual impairment test if events occur or circumstances change that would more likely than not reduce the fair value of the Company or its assets below their carrying amounts. No events have occurred since June 30, 2012, that would trigger further impairment testing of the Company’s intangible assets and goodwill. Amortization expense for the three months ended March 31, 2013 and March 31, 2012 totaled $46,000 and $33,000, respectively. Other intangible assets primarily include acquired customer lists and non-compete agreements. The following table presents details of the Company’s intangible assets, related accumulated amortization, and goodwill (in thousands): <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"> <tr> <td width="46%"></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="14" align="center">As of March 31, 2013</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="14" align="center">As of December 31, 2012</td> <td valign="bottom"> </td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">Gross</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">Accumulated Amortization</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">Impairment</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">Net</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">Gross</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">Accumulated Amortization</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">Impairment</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">Net</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Patents (4-10 years) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,914</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(1,865</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> — </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">49</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,914</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(1,833</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> — </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">81</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr> <td valign="top"> Trademarks (6 years) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">69</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(69</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right">— </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right">— </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">69</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(69</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right">— </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right">— </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Other (4 to 6 years) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">817</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(612</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right">— </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">205</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">817</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(598</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right">— </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">219</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> </tr> <tr> <td valign="top"> Total </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,800</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(2,546</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right">— </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">254</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,800</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(2,500</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right">— </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">300</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Goodwill (Indefinite life) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,926</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,926</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,926</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,926</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> </tr> </table> </div>

</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>

<us-gaap:SalesRevenueNet contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_A00DA052-212E-4E5F-A7B6-0262EF095DF3_1_2"> 14597000 </us-gaap:SalesRevenueNet>

<us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_4DB91CB0-1518-4BBC-9D34-97A2604088B3_1_12"> -1047000 </us-gaap:IncreaseDecreaseInAccountsReceivable>

<us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_A00DA052-212E-4E5F-A7B6-0262EF095DF3_1_19"> -56000 </us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>

<us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" id="id_1838087_7E9C9EC5-3BE8-4CA7-ADB0-F4CAB1478255_1_0">

<div> The stock option fair values were estimated using the Black-Scholes option-pricing model with the following assumptions: <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="76%" align="center"> <tr> <td width="76%"></td> <td valign="bottom" width="10%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="10%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="6" align="center">Three Months Ended March 31,</td> <td valign="bottom"> </td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">2013</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">2012</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Expected term </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3.7 years</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4.1 years</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr> <td valign="top"> Volatility </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">92.70</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">102</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Annual dividend per share </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.00</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.00</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr> <td valign="top"> Risk-free interest rate </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0.80</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0.93</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> </table> </div>

</us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock>

<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_A00DA052-212E-4E5F-A7B6-0262EF095DF3_1_15"> -3003000 </us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>

<us-gaap:SellingAndMarketingExpense contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_A00DA052-212E-4E5F-A7B6-0262EF095DF3_1_6"> 5252000 </us-gaap:SellingAndMarketingExpense>

<us-gaap:IncomeTaxReconciliationTaxCredits contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" decimals="0" id="id_1838087_2CD4E05E-9A11-4268-A3E0-D211E17678D3_1_0"> 214000 </us-gaap:IncomeTaxReconciliationTaxCredits>

<us-gaap:EarningsPerShareBasic contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_1838087_A00DA052-212E-4E5F-A7B6-0262EF095DF3_1_22"> -0.08 </us-gaap:EarningsPerShareBasic>

<us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_A00DA052-212E-4E5F-A7B6-0262EF095DF3_1_8"> 1005000 </us-gaap:ResearchAndDevelopmentExpense>

<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_4DB91CB0-1518-4BBC-9D34-97A2604088B3_1_27"> 1700000 </us-gaap:NetCashProvidedByUsedInFinancingActivities>

<us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" decimals="0" id="id_1838087_F5411727-EC2E-4299-AACA-CD650501D310_1_0"> 0 </us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease>

<us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" id="id_1838087_550C5F61-A3C7-4F87-82E5-0DD235108A8F_1_0">

<div> Changes in the initial product warranty accrual, and the expenses incurred under our initial and extended warranties, for the three months ended March 31, 2013 and 2012 were as follows (in thousands): <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="76%" align="center"> <tr> <td width="82%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="6" align="center">Three Months Ended March 31,</td> <td valign="bottom"> </td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">2013</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">2012</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Initial warranty accrual, beginning balance </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,699</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,218</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr> <td valign="top"> Provision for estimated warranty cost </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">650</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">122</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Warranty expenditures </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(594</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(414</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> </tr> <tr> <td valign="top"> Initial warranty accrual, ending balance </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,755</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,926</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Total warranty accrual, long term </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right">— </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right">— </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> </tr> <tr> <td valign="top"> Total warranty accrual, current portion </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,755</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,926</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> </tr> </table> </div>

</us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock>

<us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" id="id_1838087_D56367E0-A45C-49B7-82CA-804D2B42C87C_1_0">

<div> NOTE 5 – PROPERTY, PLANT, AND EQUIPMENT Property, plant, and equipment, net is comprised of the following (in thousands): <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="76%" align="center"> <tr> <td width="76%"></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">March 31, 2013</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">December 31, 2012</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Land </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">185</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">191</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr> <td valign="top"> Building </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">238</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">246</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Leasehold improvements </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,201</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,193</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr> <td valign="top"> Equipment and computers </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,439</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,219</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Furniture and fixtures </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,046</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,046</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr> <td valign="top"> Construction in progress </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">120</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">132</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8,229</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8,027</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr> <td valign="top"> Accumulated depreciation and amortization </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(6,613</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(6,518</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Property, plant, and equipment, net </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,616</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,509</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> </tr> </table> Depreciation and amortization expense related to property, plant, and equipment totaled $99,000 and $92,000 for the three months ended March 31, 2013 and 2012, respectively. </div>

</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>

<us-gaap:OperatingExpenses contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_A00DA052-212E-4E5F-A7B6-0262EF095DF3_1_10"> 8611000 </us-gaap:OperatingExpenses>

<us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_A00DA052-212E-4E5F-A7B6-0262EF095DF3_1_13"> -87000 </us-gaap:InterestIncomeExpenseNonoperatingNet>

<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" unitRef="pure" decimals="4" id="id_1838087_F5FACDCD-D74B-4383-8D73-8F77367ED3F7_1_1"> 0.9270 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>

<us-gaap:AccountingChangesAndErrorCorrectionsTextBlock contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" id="id_1838087_E140FA62-0EEC-412F-A725-FF270035DA64_1_0">

<div> NOTE 2 – RECENT ACCOUNTING PRONOUNCEMENTS Changes to U.S. GAAP are established by the Financial Accounting Standards Board (“FASB”) in the form of accounting standards updates (“ASU’s”) to the FASB’s Accounting Standards Codification (“ASC”). The Company considers the applicability and impact of all ASU’s. ASU’s not listed below were assessed and determined to not be applicable or are expected to have minimal impact on the Company’s consolidated financial position and results of operations. Newly Adopted Accounting Standards In July 2012, the FASB simplified guidance for testing for impairment of indefinite-lived intangible assets other than goodwill. The changes are intended to reduce compliance costs. The revised guidance allows a qualitative approach for testing indefinite-lived intangible assets for impairment, similar to the recently issued impairment testing guidance for goodwill and allows the option to first assess qualitative factors (events and circumstances) that could have affected the significant inputs used in determining the fair value of the indefinite-lived intangible asset to determine whether it is more likely than not (meaning a likelihood of more than 50 percent) that the indefinite-lived intangible asset is impaired. An organization may choose to bypass the qualitative assessment for any indefinite-lived intangible asset in any period and proceed directly to calculating its fair value. The amendments are effective for annual and interim impairment tests performed for fiscal years beginning after September 15, 2012. The adoption did not have a material impact on the Company’s consolidated financial statements. In February 2013, the FASB issued guidance for reporting of amounts reclassified out of accumulated other comprehensive income. The revised guidance requires reporting the effect of significant reclassifications out of accumulated other comprehensive income on the respective line items in net income if the amount being reclassified is required to be reclassified in its entirety to net income. For other amounts that are not required to be reclassified in their entirety to net income in the same reporting period, an entity is required to cross-reference other disclosures that provide additional detail about these amounts. The amendments do not change the current requirements for reporting net income or other comprehensive income in financial statements. The guidance is effective prospectively for reporting periods beginning after December 15, 2012. The adoption did not have a material impact on the Company’s consolidated financial statements. New Accounting Standards Not Yet Adopted In March 2013, the FASB issued guidance on a parent’s accounting for the cumulative translation adjustment upon derecognition of certain subsidiaries or groups of assets within a foreign entity or of an investment in a foreign entity. The revised guidance requires that the parent release any related cumulative translation adjustment into net income only if the sale or transfer results in the complete or substantially complete liquidation of the foreign entity in which the subsidiary or group of assets had resided. The guidance is effective prospectively for reporting periods beginning after December 15, 2013. Early adoption is permitted. Management believes that the adoption of this guidance will not have a material impact on the Company’s consolidated financial statements. </div>

</us-gaap:AccountingChangesAndErrorCorrectionsTextBlock>

<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" unitRef="shares" decimals="-3" id="id_1838087_A00DA052-212E-4E5F-A7B6-0262EF095DF3_1_25"> 31473000 </us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>

<us-gaap:IncomeTaxDisclosureTextBlock contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" id="id_1838087_C39E5458-A430-4BBB-AE01-F8D54D7FD0F6_1_0">

<div> NOTE 12—INCOME TAXES The Company accounts for income taxes under the asset and liability method, whereby deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Management evaluates the need to establish a valuation allowance for deferred tax assets based upon the amount of existing temporary differences, the period in which they are expected to be recovered, and expected levels of taxable income. A valuation allowance to reduce deferred tax assets is established when it is “more likely than not” that some or all of the deferred tax assets will not be realized. Management has determined that a full valuation allowance against the Company’s net deferred tax assets is appropriate. As of March 31, 2013, the Company had net operating loss (“NOL”) carryforwards for federal and state purposes of approximately $69.5 million and $45.3 million, respectively, which begin to expire in 2013. The utilization of NOL and credit carryforwards may be limited under the provisions of the Internal Revenue Code (“IRC”) Section 382 and similar state provisions. IRC Section 382 generally imposes an annual limitation on the amount of NOL carryforwards that may be used to offset taxable income where a corporation has undergone significant changes in stock ownership. During the year ended December 31, 2006, the Company completed an analysis to determine the potential applicability of any annual limitations imposed by IRC Section 382. Based on the analysis, management determined that there was no significant IRC Section 382 limitation. As of March 31, 2013, the Company had research and development tax credit carryforwards for federal and state purposes of approximately $954,000 and $516,000, respectively, which will begin to expire in 2018 for federal purposes and will carryforward indefinitely for state purposes. An updated analysis may be required at the time the Company begins utilizing any of its net operating losses to determine if there is an IRC Section 382 limitation. Accounting for uncertainty in income taxes prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return and provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition. The Company has elected to classify interest and penalties as a component of its income tax provision. For the three months ended March 31, 2013 and 2012, the Company recorded an increase of $0 and $1,000, respectively, with respect to the liability for unrecognized tax benefits, including related estimates of penalties and interest. During the three months ended March 31, 2013, the Company reversed certain deferred tax liabilities associated with international operations and research and development credits resulting in a tax benefit of approximately $214,000. During the three months ended March 31, 2013, the Company recorded an income tax benefit of $158,000 based on its projected annual effective tax rate of 4.9% for the year ending December 31, 2013. The effective tax rate differs from the statutory tax rate of 34% primarily due to the existence of valuation allowances against net deferred tax assets and current liabilities resulting from the estimated state income tax liabilities and federal alternative minimum tax liability. Recently enacted tax laws may also affect the tax provision on the Company’s financial statements. The state of California requires the use of a single sales factor apportionment formula for tax years beginning on or after January 1, 2013. The Company’s state deferred tax assets will be revalued to account for the change in the tax law during the quarter ending June 30, 2013. The Company records a full valuation allowance against the state deferred tax assets therefore the California apportionment mandate is not expected to have a material impact on the Company’s consolidated financial statements. </div>

</us-gaap:IncomeTaxDisclosureTextBlock>

<us-gaap:IncreaseDecreaseInInventories contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_4DB91CB0-1518-4BBC-9D34-97A2604088B3_1_13"> 779000 </us-gaap:IncreaseDecreaseInInventories>

<us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" unitRef="pure" decimals="2" id="id_1838087_F0A3794A-0445-411C-BF60-DBDBBD5B085B_1_2"> 0.34 </us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>

<us-gaap:ConsolidationPolicyTextBlock contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" id="id_1838087_6B3B5720-D9C6-45DB-B83E-59A737E7CB79_1_0">

<div> Basis of Presentation The unaudited consolidated financial statements include the accounts of BIOLASE, Inc. and its wholly-owned subsidiaries and have been prepared on a basis consistent with the December 31, 2012 audited consolidated financial statements and include all material adjustments, consisting of normal recurring adjustments and the elimination of all material intercompany transactions and balances, necessary to fairly present the information set forth therein. These unaudited, interim, consolidated financial statements do not include all the footnotes, presentations and disclosures normally required by accounting principles generally accepted in the United States of America (“GAAP”) for complete consolidated financial statements. Certain amounts have been reclassified to conform to current period presentations. The consolidated results of operations for the three months ended March 31, 2013 are not necessarily indicative of the results for the full year. The accompanying consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto for the year ended December 31, 2012, included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2012 (“2012 Form 10-K”) filed with the Securities and Exchange Commission on March 15, 2013. </div>

</us-gaap:ConsolidationPolicyTextBlock>

<us-gaap:DeferredRevenueByArrangementDisclosureTextBlock contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" id="id_1838087_771EA4EE-A60D-4CC9-8C02-9F3565BEC0EB_1_0">

<div> Deferred revenue is comprised of the following (in thousands): <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="76%" align="center"> <tr> <td width="68%"></td> <td valign="bottom" width="12%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="12%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">March 31, 2013</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">December 31, 2012</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Undelivered elements (training, installation and product and support services) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,623</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,723</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr> <td valign="top"> Extended warranty contracts </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,510</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,506</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Total deferred revenue </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,133</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,229</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> </tr> <tr> <td valign="top"> Less long-term amounts: </td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Extended warranty contracts </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(2</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(3</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> </tr> <tr> <td valign="top"> Total deferred revenue, long-term </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(2</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(3</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Total deferred revenue, current portion </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,131</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,226</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> </tr> </table> </div>

</us-gaap:DeferredRevenueByArrangementDisclosureTextBlock>

<us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" id="id_1838087_9D019195-1006-4275-AED6-16098493B4FF_1_0">

<div> Accrued liabilities are comprised of the following (in thousands): <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="76%" align="center"> <tr> <td width="68%"></td> <td valign="bottom" width="11%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="11%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">March 31, 2013</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">December 31, 2012</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Payroll and benefits </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,613</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,326</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr> <td valign="top"> Warranty accrual </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,755</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,699</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Sales tax </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">421</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">640</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr> <td valign="top"> Accrued professional services </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">650</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">502</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Accrued insurance premium </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">326</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">751</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr> <td valign="top"> Other </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">114</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">349</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Accrued liabilities </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,879</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,267</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> </tr> </table> </div>

</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>

<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" unitRef="shares" decimals="INF" id="id_1838087_10F7D60D-6A98-40A4-B210-EFAE99262C14_5001_400005"> 106000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>

<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" id="id_1838087_508E2DB3-CE43-45B3-9FE3-A95F6A5B48C6_2001_2"> P3Y10M24D </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>

<us-gaap:CostOfGoodsSold contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_A00DA052-212E-4E5F-A7B6-0262EF095DF3_1_3"> 8803000 </us-gaap:CostOfGoodsSold>

<us-gaap:IncomeTaxUncertaintiesPolicy contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" id="id_1838087_88482AB9-92BD-4F45-8EE5-3A57A8C7AAE8_1_0">

<div> Accounting for uncertainty in income taxes prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return and provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition. The Company has elected to classify interest and penalties as a component of its income tax provision. For the three months ended March 31, 2013 and 2012, the Company recorded an increase of $0 and $1,000, respectively, with respect to the liability for unrecognized tax benefits, including related estimates of penalties and interest. </div>

</us-gaap:IncomeTaxUncertaintiesPolicy>

<us-gaap:InventoryDisclosureTextBlock contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" id="id_1838087_29FEA720-740F-4BA0-878D-11D401E4C491_1_0">

<div> NOTE 4 - INVENTORY Inventory is valued at the lower of cost or market (determined by the first-in, first-out method) and is comprised of the following (in thousands): <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="76%" align="center"> <tr> <td width="76%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">March 31, 2013</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">December 31, 2012</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Raw materials </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,023</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,017</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr> <td valign="top"> Work-in-process </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,954</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,949</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Finished goods </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,944</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,176</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> </tr> <tr> <td valign="top"> Inventory, net </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">11,921</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">11,142</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> </tr> </table> Inventory is net of the provision for excess and obsolete inventory totaling $1.9 million as of March 31, 2013 and December 31, 2012. </div>

</us-gaap:InventoryDisclosureTextBlock>

<us-gaap:IncomeTaxesPaidNet contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_4DB91CB0-1518-4BBC-9D34-97A2604088B3_1_34"> 45000 </us-gaap:IncomeTaxesPaidNet>

<us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_053476C4-3EF5-4933-8AA5-88BFA09A7E6B_1_0"> 368000 </us-gaap:AllocatedShareBasedCompensationExpense>

<us-gaap:DividendsPayableDateOfRecordDayMonthAndYear contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" id="id_1838087_CF38A140-4253-41AE-9E72-55B77B0C0D93_1_0"> 2013-03-15 </us-gaap:DividendsPayableDateOfRecordDayMonthAndYear>

<us-gaap:GrossProfit contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_A00DA052-212E-4E5F-A7B6-0262EF095DF3_1_4"> 5794000 </us-gaap:GrossProfit>

<us-gaap:DebtDisclosureTextBlock contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" id="id_1838087_726F153E-E66C-491F-9E68-8DBAB9E46B2C_1_0">

<div> NOTE 8—LINES OF CREDIT AND OTHER BORROWINGS Lines of Credit During the year ended December 31, 2012, the Company entered into and amended two revolving credit facility agreements with Comerica Bank (the “Credit Agreements”), which provide for borrowings against certain domestic accounts receivable and inventory, as set forth in the $4.0 million revolving credit facility agreement (the “Domestic Revolver”), and borrowings against certain export related accounts receivable and inventory, as set forth in the $4.0 million revolving credit facility agreement (the “Ex-Im Revolver”), for a combined aggregate commitment of borrowings up to $8.0 million. The lines of credit mature on May 1, 2014, at which date any remaining borrowings and accrued interest under the lines of credit become due and payable. As of March 31, 2013, the Company had outstanding borrowings totaling approximately $3.3 million, which included $1.8 million under the Domestic Revolver and $1.5 million under the Ex-Im Revolver. Lockbox arrangements under the revolving bank facilities provide that substantially all of the income generated is deposited directly into lockbox accounts and then swept into cash management accounts for the benefit of Comerica Bank. Cash is disbursed from Comerica Bank to the Company only after payment of the applicable debt service and principal. At March 31, 2013, there were no restricted cash amounts. The Company’s obligations are generally secured by substantially all of the Company’s assets now owned or hereinafter acquired. The Credit Agreements require the Company to maintain compliance with certain financial and non-financial covenants, as defined therein. If a default occurs, Comerica Bank may declare the amounts outstanding under the Credit Agreements immediately due and payable. As of March 31, 2013, the Company was in compliance with these covenants. The interest rates on the outstanding principal balance of the credit facilities bear interest at annual percentage rates equal to the daily adjusting LIBOR rate, plus spreads of 5.25% for the Domestic Revolver and 4.25% for the Ex-Im Revolver. The daily adjusting LIBOR rate is subject to a floor of 1.00% per annum. The Company is also required to pay an unused commitment fee of 0.25% based on a portion of the undrawn lines of credit, payable quarterly in arrears. During the three months ended March 31, 2013, the Company incurred $84,000 of interest expense associated with the credit facilities, of which approximately $18,000 was payable at March 31, 2013. Included in interest expense during the three months ended March 31, 2013 is $38,000 of amortization of deferred debt issuance costs and $18,000 of amortization of the discount on lines of credit. During the year ended December 31, 2012, the Company issued and amended warrants to Comerica Bank (the “Comerica Warrants”) to purchase up to 80,000 shares of the Company’s common stock at an amended exercise price of $2.00. During the three months ended March 31, 2013, Comerica Bank exercised 80,000 warrants on a cashless basis pursuant to the Notice of Exercise resulting in a net issuance of 40,465 shares of common stock. Other Borrowings The Company finances a portion of its annual insurance premiums which it pays in installments over nine months. As of March 31, 2013, $212,000 at an annual interest rate of 3.0% was outstanding under this arrangement. The Company incurred interest expense associated with the financed insurance premiums of approximately $2,000 during the three months ended March 31, 2013. </div>

</us-gaap:DebtDisclosureTextBlock>

<us-gaap:OperatingLossCarryforwardsExpirationDates contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" id="id_1838087_4CD013EE-034E-4E26-A7F7-2E9282E137A7_1_2"> 2013 </us-gaap:OperatingLossCarryforwardsExpirationDates>

<us-gaap:InterestPaid contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_4DB91CB0-1518-4BBC-9D34-97A2604088B3_1_33"> 31000 </us-gaap:InterestPaid>

<us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" id="id_1838087_8A5BB57A-9DD0-43B6-BF74-A870439C80E8_1_0">

<div> NOTE 9—COMMITMENTS AND CONTINGENCIES Leases The Company leases its corporate headquarters and manufacturing facility in Irvine, California, and also leases certain other facilities, office equipment, and automobiles under various operating lease arrangements. Future minimum rental commitments under operating lease agreements with non-cancelable terms greater than one year for the years ending December 31, 2013, 2014, 2015, and 2016 and thereafter, is $806,000, $659,000, $192,000, and $0, respectively. Employee arrangements and other compensation Certain members of management are entitled to severance benefits payable upon termination following a change in control, which would approximate $714,000 at March 31, 2013. The Company also has agreements with certain employees to pay bonuses based on targeted performance criteria. No amount was required to be accrued at March 31, 2013. Purchase Commitments The Company generally purchases components and subassemblies for its products from a limited group of third party suppliers through purchase orders. The Company had $12.9 million of purchase commitments as of March 31, 2013, for which the Company has not received the goods or services and which is expected to be purchased within one year. These purchase commitments were made to secure better pricing and to ensure the Company will have the necessary parts to meet anticipated near term demand. Litigation The Company discloses material loss contingencies deemed to be reasonably possible and accrues for loss contingencies when, in consultation with its legal advisors, management concludes that a loss is probable and reasonably estimable. The ability to predict the ultimate outcome of such matters involves judgments, estimates, and inherent uncertainties. The actual outcome of such matters could differ materially from management’s estimates. Intellectual Property Litigation On April 24, 2012, CAO Group, Inc. (“CAO”) filed a lawsuit against the Company in the United States District Court for the District of Utah, Central Division, alleging patent infringement of U.S. Patent No. 7,485,116 involving the Company’s ezLase diode laser. On September 12, 2012, CAO filed a First Amended Complaint, which added claims for (1) business disparagement/injurious falsehood and (2) unfair competition. The new claims are based on a press release that the Company issued on or about April 30, 2012, which CAO alleges contain statements that are factually inaccurate and falsities that are disparaging to CAO and its diode product. The First Amended Complaint seeks unspecified damages, punitive damages, injunctive relief, treble damages, costs, interest, and attorneys’ fees. On September 14, 2012, the Company filed an inter partes reexamination request with respect to the asserted patent with the United States Patent and Trademark Office (“USPTO”). The Court then entered a stay of the lawsuit pending the request for reexamination, which reexamination request was subsequently granted. The USPTO issued an office action in a reexamination proceeding rejecting all of the claims of CAO that were subject to reexamination. Because all of the pertinent patent claims being asserted by CAO against the Company in the lawsuit have been reexamined by the USPTO, the District Court has stayed CAO’s lawsuit pending the final outcome of the reexamination. Management plans to vigorously defend against the allegations. Other Matters In the normal course of business, the Company is subject to other legal proceedings, lawsuits and other claims. Although the ultimate aggregate amount of probable monetary liability or financial impact with respect to these matters is subject to many uncertainties and is therefore not predictable with assurance, the Company’s management believes that any monetary liability or financial impact to the Company from these other matters, individually and in the aggregate, would not be material to the Company’s financial condition, results of operations or cash flows. However, there can be no assurance with respect to such result, and monetary liability or financial impact to the Company from these other matters could differ materially from those projected. </div>

</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>

<us-gaap:SegmentReportingDisclosureTextBlock contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" id="id_1838087_4E6321D8-3FED-470D-9675-97532B17F196_1_0">

<div> NOTE 10— SEGMENT INFORMATION The Company currently operates in a single reportable segment. For the quarter ended March 31, 2013, sales in the United States accounted for approximately 62% of net revenue, and international sales accounted for approximately 38% of net revenue. For the quarter ended March 31, 2012, sales in the United States accounted for approximately 68% of net revenue, and international sales accounted for approximately 32% of net revenue. Net revenue by geographic location based on the location of customers was as follows (in thousands): <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="76%" align="center"> <tr> <td width="80%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="6" align="center">Three Months Ended March 31,</td> <td valign="bottom"> </td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">2013</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">2012</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> United States </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">9,048</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">8,364</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr> <td valign="top"> International </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,549</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,956</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">14,597</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">12,320</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> </tr> </table> No individual country, other than the United States, represents more than 10% of total net revenue. Long-lived assets located outside of the United States at our foreign subsidiaries totaled $397,000 and $412,000 as of March 31, 2013 and December 31, 2012, respectively. </div>

</us-gaap:SegmentReportingDisclosureTextBlock>

<us-gaap:PaymentsToAcquireIntangibleAssets contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_4DB91CB0-1518-4BBC-9D34-97A2604088B3_1_21"> 10000 </us-gaap:PaymentsToAcquireIntangibleAssets>

<us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_4DB91CB0-1518-4BBC-9D34-97A2604088B3_1_10"> -107000 </us-gaap:DeferredIncomeTaxExpenseBenefit>

<us-gaap:AmortizationOfDebtDiscountPremium contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" decimals="0" id="id_1838087_65E0AFDA-8528-43B0-8417-3ED2204F154C_1_9"> 18000 </us-gaap:AmortizationOfDebtDiscountPremium>

<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" unitRef="shares" decimals="INF" id="id_1838087_9F5FAA7E-3B9D-460F-9024-6FC808FA9242_1_0"> 5060000 </us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>

<us-gaap:NetIncomeLoss contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_A00DA052-212E-4E5F-A7B6-0262EF095DF3_1_17"> -2631000 </us-gaap:NetIncomeLoss>

<us-gaap:NonoperatingIncomeExpense contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_A00DA052-212E-4E5F-A7B6-0262EF095DF3_1_14"> -186000 </us-gaap:NonoperatingIncomeExpense>

<us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_A00DA052-212E-4E5F-A7B6-0262EF095DF3_1_12"> -99000 </us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>

<us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" id="id_1838087_21489103-86E3-4BCB-A13A-3151BC97D11A_1_0">

<div> The following table summarizes the income statement classification of compensation expense associated with share-based payments (in thousands): <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="76%" align="center"> <tr> <td width="84%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="6" align="center">Three Months Ended March 31,</td> <td valign="bottom"> </td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">2013</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">2012</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Cost of revenue </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">80</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">58</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr> <td valign="top"> Sales and marketing </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">139</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">121</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> General and administrative </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">115</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">358</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr> <td valign="top"> Engineering and development </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">34</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">46</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">368</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">583</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> </tr> </table> </div>

</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>

<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" unitRef="shares" decimals="INF" id="id_1838087_10F7D60D-6A98-40A4-B210-EFAE99262C14_5001_400003"> 612000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>

<us-gaap:IncomeTaxExpenseBenefit contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_A00DA052-212E-4E5F-A7B6-0262EF095DF3_1_16"> -372000 </us-gaap:IncomeTaxExpenseBenefit>

<us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_4DB91CB0-1518-4BBC-9D34-97A2604088B3_1_28"> -43000 </us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>

<us-gaap:UseOfEstimates contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" id="id_1838087_AD4056B2-1F31-4412-A7F6-087B29B272A1_1_0">

<div> Use of Estimates The preparation of these consolidated financial statements in conformity with GAAP requires the Company to make estimates and assumptions that affect amounts reported in the consolidated financial statements and the accompanying notes. Significant estimates in these consolidated financial statements include allowances on accounts receivable, inventory, and deferred taxes, as well as estimates for accrued warranty expenses, indefinite-lived intangible assets, and the ability of goodwill to be realized, revenue deferrals for multiple element arrangements, effects of stock-based compensation and warrants, contingent liabilities and the provision or benefit for income taxes. Due to the inherent uncertainty involved in making estimates, actual results reported in future periods may differ materially from those estimates. </div>

</us-gaap:UseOfEstimates>

<us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" id="id_1838087_75AEF62A-1082-4EC1-BE2A-2BF6216CF9FA_1_0">

<div> NOTE 1 – BASIS OF PRESENTATION The Company BIOLASE, Inc., (the “Company”) incorporated in Delaware in 1987, is a biomedical company operating in one reportable business segment that develops, manufactures, and markets lasers in dentistry and medicine and also markets and distributes dental imaging equipment, including cone beam digital x-rays and CAD/CAM intra-oral scanners. Basis of Presentation The unaudited consolidated financial statements include the accounts of BIOLASE, Inc. and its wholly-owned subsidiaries and have been prepared on a basis consistent with the December 31, 2012 audited consolidated financial statements and include all material adjustments, consisting of normal recurring adjustments and the elimination of all material intercompany transactions and balances, necessary to fairly present the information set forth therein. These unaudited, interim, consolidated financial statements do not include all the footnotes, presentations and disclosures normally required by accounting principles generally accepted in the United States of America (“GAAP”) for complete consolidated financial statements. Certain amounts have been reclassified to conform to current period presentations. The consolidated results of operations for the three months ended March 31, 2013 are not necessarily indicative of the results for the full year. The accompanying consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto for the year ended December 31, 2012, included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2012 (“2012 Form 10-K”) filed with the Securities and Exchange Commission on March 15, 2013. Use of Estimates The preparation of these consolidated financial statements in conformity with GAAP requires the Company to make estimates and assumptions that affect amounts reported in the consolidated financial statements and the accompanying notes. Significant estimates in these consolidated financial statements include allowances on accounts receivable, inventory, and deferred taxes, as well as estimates for accrued warranty expenses, indefinite-lived intangible assets, and the ability of goodwill to be realized, revenue deferrals for multiple element arrangements, effects of stock-based compensation and warrants, contingent liabilities and the provision or benefit for income taxes. Due to the inherent uncertainty involved in making estimates, actual results reported in future periods may differ materially from those estimates. Update to Significant Accounting Policies There have been no material changes to the Company’s significant accounting policies which are described in the Company’s 2012 Form 10-K, except as noted below. See Note 2 – Recent Accounting Pronouncements for adoption of updated authoritative guidance. Excise Tax Commencing January 1, 2013, certain of the Company’s product sales are subject to the newly enacted medical device excise tax. The Company has included such taxes separately as a component of operating expense. Fair Value of Financial Instruments The Company’s financial instruments, consisting of cash and cash equivalents, accounts receivable, accounts payable, and accrued liabilities, approximate fair value because of the short maturity of these items. Financial instruments consisting of lines of credit approximate fair value, as the interest rates associated with the lines of credit approximates the market rates for debt securities with similar terms and risk characteristics. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the principal market or, if none exists, the most advantageous market, for the specific asset or liability at the measurement date (referred to as the “exit price”). The fair value should be based on assumptions that market participants would use, including a consideration of nonperformance risk. Level 1 measurement of fair value is quoted prices in active markets for identical assets or liabilities. Liquidity and Management’s Plans The Company suffered recurring losses from operations during the three years ended December 31, 2012. Although the Company’s revenues increased during the quarter ended March 31, 2013 compared to the same period in 2012, the Company still incurred a loss from operations and a net loss. At March 31, 2013, the Company had approximately $5.2 million in working capital. The Company’s principal sources of liquidity at March 31, 2013 consisted of approximately $1.2 million in cash and cash equivalents, $10.6 million of net accounts receivable, and $4.7 million of available borrowings under two revolving credit facility agreements. The Company intends to improve its financial condition and ultimately improve its financial results by increasing revenues through expansion of its product offerings and continued development of its direct sales force and distributor relationships both domestically and internationally. Furthermore, to improve liquidity, management amended the Company’s lines of credit increasing the combined aggregate capacity of borrowings to $10.0 million; see Note 13 – Subsequent Events for further discussion. Management expects that the working capital and borrowings available under the lines of credit should be sufficient to fund the requirements of the Company. Management continues to monitor the liquidity of the Company and is prepared to implement cash saving measures in the event that its plans to grow revenue do not materialize in the timeline anticipated by management. </div>

</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>

<us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" id="id_1838087_6D113965-94A2-42CE-92B5-F923BF900928_1_0">

<div> NOTE 3—STOCK-BASED AWARDS AND PER SHARE INFORMATION Stock-Based Compensation The Company currently has one stock-based compensation plan, the 2002 Stock Incentive Plan (the “2002 Plan”). Eligible persons under the 2002 Plan include certain officers and employees of the Company, and directors of the Company, as well as consultants. Under the 2002 Plan, 6,950,000 shares of common stock have been authorized for issuance. As of March 31, 2013, 2,527,000 shares of common stock have been issued pursuant to options that were exercised, 4,337,000 shares of common stock have been reserved for options that are outstanding, and 86,000 shares of common stock remain available for future grant. Compensation cost related to stock options recognized in operating results during the three months ended March 31, 2013 and 2012, totaled approximately $368,000 and $583,000, respectively. The net impact to earnings for the periods ended March 31, 2013 and 2012 was $(0.01) and $(0.01) per basic and diluted share, respectively. At March 31, 2013, the Company had approximately $2.5 million of total unrecognized compensation cost, net of estimated forfeitures, related to unvested share-based compensation arrangements granted under our existing plans. The Company expects that cost to be recognized over a weighted-average period of 1.3 years. The following table summarizes the income statement classification of compensation expense associated with share-based payments (in thousands): <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="76%" align="center"> <tr> <td width="84%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="6" align="center">Three Months Ended March 31,</td> <td valign="bottom"> </td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">2013</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">2012</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Cost of revenue </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">80</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">58</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr> <td valign="top"> Sales and marketing </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">139</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">121</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> General and administrative </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">115</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">358</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr> <td valign="top"> Engineering and development </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">34</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">46</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">368</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">583</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> </tr> </table> The stock option fair values were estimated using the Black-Scholes option-pricing model with the following assumptions: <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="76%" align="center"> <tr> <td width="76%"></td> <td valign="bottom" width="10%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="10%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="6" align="center">Three Months Ended March 31,</td> <td valign="bottom"> </td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">2013</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">2012</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Expected term </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3.7 years</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4.1 years</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr> <td valign="top"> Volatility </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">92.70</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">102</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Annual dividend per share </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.00</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.00</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr> <td valign="top"> Risk-free interest rate </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0.80</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0.93</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> </table> A summary of option activity under our stock option plans for the three months ended March 31, 2013 is as follows: <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"> <tr> <td width="60%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">Shares</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">Weighted average exercise price</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">Weighted average remaining contractual term (years)</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">Aggregate intrinsic value(1)</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Options outstanding at December 31, 2012 </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,860,000</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3.48</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> Plus: Options granted </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">612,000</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3.76</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Less: Options exercised </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(29,000</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2.53</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> Options forfeited, canceled, or expired </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(106,000</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3.68</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Options outstanding at March 31, 2013 </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,337,000</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3.47</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3.90</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,379,000</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> Options exercisable at March 31, 2013 </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,460,000</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3.84</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3.65</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,099,000</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Vested options expired during the quarter ended March 31, 2013 </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">— </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">— </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> </table> <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td valign="top" width="4%" align="left">(1)</td> <td valign="top" align="left">The intrinsic value calculation does not include negative values. This can occur when the fair market value on the reporting date is less than the exercise price of the grant.</td> </tr> </table> Cash proceeds along with fair value disclosures related to grants, exercises and vesting options are provided in the following table (in thousands, except per share amounts): <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="76%" align="center"> <tr> <td width="84%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="6" align="center">Three Months Ended March 31,</td> <td valign="bottom"> </td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">2013</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">2012</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Proceeds from stock options exercised </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">76</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">277</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr> <td valign="top"> Tax benefit related to stock options exercised (1) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">N/A</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">N/A</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Intrinsic value of stock options exercised (2) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">23</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">11</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr> <td valign="top"> Weighted-average fair value of options granted during period </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1.84</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1.99</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Total fair value of shares vested during the period </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">314</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">557</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> </table> <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td valign="top" width="4%" align="left">(1)</td> <td valign="top" align="left">Excess tax benefits received related to stock option exercises are presented as financing cash inflows. We currently do not receive a tax benefit related to the exercise of stock options due to our net operating losses.</td> </tr> </table> <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td valign="top" width="4%" align="left">(2)</td> <td valign="top" align="left">The intrinsic value of stock options exercised is the amount by which the market price of the stock on the date of exercise exceeded the market price of the stock on the date of grant.</td> </tr> </table> Warrants On March 23, 2013, the Company issued warrants to purchase up to 50,000 shares of the Company’s common stock to a consultant, at a price per share of $4.50. The warrants vest and become exercisable only if the Company’s common stock closing price on NASDAQ reaches or exceeds $7.50. The warrant expires March 22, 2018. The issuance includes a bonus award of up to 50,000 additional shares if a $10.00 closing price on NASDAQ is achieved. As of March 31, 2013, no stock-based compensation has been recognized. The Company will reassess whether achievement of the contingent exercise provision is probable on a quarterly basis and recognize stock-based compensation when it is probable that the market performance requirement will be achieved. Warrants issued in connection with the lines of credit with Comerica Bank were exercised during the three months ended March 31, 2013. See Note 8 – Lines of Credit and Other Borrowings for further discussion. Net Loss Per Share - Basic and Diluted Basic net loss per share is computed by dividing loss available to common stockholders by the weighted-average number of common shares outstanding for the period. In computing diluted net loss per share, the weighted average number of shares outstanding is adjusted to reflect the effect of potentially dilutive securities. Outstanding stock options and warrants to purchase 5,060,000 shares were not included in the computation of diluted loss per share for the three months ended March 31, 2013 as a result of their anti-dilutive effect. For the same 2012 period, anti-dilutive outstanding stock options and warrants to purchase 4,514,000 shares were not included in the computation of diluted loss per share. Stock Dividends The Company intends to pay a 2% annual stock dividend, in quarterly installments, for the year ending December 31, 2013. Stock dividends are discussed quarterly by the Board and management. The actual declaration of future stock dividends and the establishment of the record and payment dates are subject to final determination by the Board after its review of the Company’s financial performance, the expected results of future operations, availability of shares, and other factors that the Board may deem relevant. The Company’s dividend policy may be changed at any time by the Board, and there is no assurance, with respect to the amount or frequency, that any stock dividend will be declared in the future. In February 2013, the Board declared a one-half percent stock dividend payable March 29, 2013 to stockholders of record on March 15, 2013. The Board deems this stock dividend to be a special dividend and there is no assurance, with respect to amount or frequency, that any stock dividend will be declared again in the future. All stock information presented, other than that related to stock options and warrants, has been adjusted to reflect the effects of the dividend. </div>

</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>

<us-gaap:AmortizationOfIntangibleAssets contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" decimals="0" id="id_1838087_5C3FF8A6-54CB-4B64-B6AC-506288609EB6_1_0"> 46000 </us-gaap:AmortizationOfIntangibleAssets>

<us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" id="id_1838087_8F89E667-E3D4-423C-8D1E-A190933E07AF_1_0">

<div> Fair Value of Financial Instruments The Company’s financial instruments, consisting of cash and cash equivalents, accounts receivable, accounts payable, and accrued liabilities, approximate fair value because of the short maturity of these items. Financial instruments consisting of lines of credit approximate fair value, as the interest rates associated with the lines of credit approximates the market rates for debt securities with similar terms and risk characteristics. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the principal market or, if none exists, the most advantageous market, for the specific asset or liability at the measurement date (referred to as the “exit price”). The fair value should be based on assumptions that market participants would use, including a consideration of nonperformance risk. Level 1 measurement of fair value is quoted prices in active markets for identical assets or liabilities. </div>

</us-gaap:FairValueOfFinancialInstrumentsPolicy>

<us-gaap:LiquidityDisclosureGoingConcernNote contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" id="id_1838087_4303F1DD-6AF6-42F3-AA3A-773913C066C6_1_0"> The working capital and borrowings available under the lines of credit should be sufficient to fund the requirements of the Company. </us-gaap:LiquidityDisclosureGoingConcernNote>

<us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" id="id_1838087_58B14219-CC07-4B9A-A0C3-AC8E035F55FA_1_0">

<div> The Company conducted its annual impairment test of intangible assets and goodwill as of June 30, 2012, and determined that there was no impairment. The Company also tests its intangible assets and goodwill between the annual impairment test if events occur or circumstances change that would more likely than not reduce the fair value of the Company or its assets below their carrying amounts. No events have occurred since June 30, 2012, that would trigger further impairment testing of the Company’s intangible assets and goodwill. </div>

</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>

<us-gaap:DebtIssuanceCosts contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" decimals="INF" id="id_1838087_65E0AFDA-8528-43B0-8417-3ED2204F154C_1_8"> 38000 </us-gaap:DebtIssuanceCosts>

<us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" id="id_1838087_E8D8C22F-7CE0-4C7B-8FCA-5B82155CBC85_1_0">

<div> The following table presents details of the Company’s intangible assets, related accumulated amortization, and goodwill (in thousands): <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"> <tr> <td width="46%"></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="14" align="center">As of March 31, 2013</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="14" align="center">As of December 31, 2012</td> <td valign="bottom"> </td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">Gross</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">Accumulated Amortization</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">Impairment</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">Net</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">Gross</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">Accumulated Amortization</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">Impairment</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">Net</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Patents (4-10 years) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,914</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(1,865</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> — </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">49</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,914</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(1,833</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> — </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">81</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr> <td valign="top"> Trademarks (6 years) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">69</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(69</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right">— </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right">— </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">69</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(69</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right">— </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right">— </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Other (4 to 6 years) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">817</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(612</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right">— </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">205</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">817</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(598</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right">— </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">219</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> </tr> <tr> <td valign="top"> Total </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,800</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(2,546</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right">— </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">254</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,800</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(2,500</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right">— </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">300</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Goodwill (Indefinite life) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,926</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,926</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,926</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,926</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> </tr> </table> </div>

</us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock>

<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_1838087_643BC9AC-CC98-4735-8599-488FD13A80CB_1_3"> 1.84 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>

<biol:EntityWideRevenueMajorCustomerNumber contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" unitRef="Customer" decimals="INF" id="id_1838087_EACBDC32-9092-47B0-AA70-97988FB2993A_1_0"> 0 </biol:EntityWideRevenueMajorCustomerNumber>

<biol:EntityWideAccountsReceivableMajorCustomerNumber contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" unitRef="Customer" decimals="INF" id="id_1838087_5F4F3C59-2E29-42BC-9096-5BBD3DA1B956_1_0"> 0 </biol:EntityWideAccountsReceivableMajorCustomerNumber>

<biol:ExciseTaxesPolicyTextBlock contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" id="id_1838087_D82A1FC5-7A90-48D5-9574-B4F390FA89B9_1_0">

<div> Excise Tax Commencing January 1, 2013, certain of the Company’s product sales are subject to the newly enacted medical device excise tax. The Company has included such taxes separately as a component of operating expense. </div>

</biol:ExciseTaxesPolicyTextBlock>

<biol:IndefiniteLivedIntangibleAssetsUsefulLife contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" id="id_1838087_E7B02AA9-ED37-46CC-BFCC-ABD1E4DCFCD9_4001_1"> Indefinite life </biol:IndefiniteLivedIntangibleAssetsUsefulLife>

<biol:OtherEquityInstrumentsCompensation contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_4DB91CB0-1518-4BBC-9D34-97A2604088B3_1_8"> 64000 </biol:OtherEquityInstrumentsCompensation>

<biol:LicenseFeesAndRoyaltyRevenue contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_A00DA052-212E-4E5F-A7B6-0262EF095DF3_1_1"> 108000 </biol:LicenseFeesAndRoyaltyRevenue>

<biol:DepreciationDepletionAndAmortizationOfPropertyPlantAndEquipment contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" decimals="0" id="id_1838087_0AB21D10-75AF-44BE-B0CE-62F7741FC060_1_0"> 99000 </biol:DepreciationDepletionAndAmortizationOfPropertyPlantAndEquipment>

<biol:NumberRevolvingCreditFacilityAgreements contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" unitRef="Agreement" decimals="0" id="id_1838087_4E2A4F6E-4575-4C29-B5AF-C6EDEA1716BC_2_4"> 2 </biol:NumberRevolvingCreditFacilityAgreements>

<biol:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividend contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_1838087_F5FACDCD-D74B-4383-8D73-8F77367ED3F7_1_2"> 0.00 </biol:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividend>

<biol:CashProceedsAlongWithFairValueDisclosuresRelatedToGrantsExercisesAndVestingOptionsTableTextBlock contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" id="id_1838087_B3D4A6AB-8961-4B05-B98B-3D2A27E944CC_1_0">

<div> Cash proceeds along with fair value disclosures related to grants, exercises and vesting options are provided in the following table (in thousands, except per share amounts): <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="76%" align="center"> <tr> <td width="84%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="6" align="center">Three Months Ended March 31,</td> <td valign="bottom"> </td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">2013</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">2012</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Proceeds from stock options exercised </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">76</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">277</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr> <td valign="top"> Tax benefit related to stock options exercised (1) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">N/A</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">N/A</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Intrinsic value of stock options exercised (2) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">23</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">11</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr> <td valign="top"> Weighted-average fair value of options granted during period </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1.84</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1.99</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Total fair value of shares vested during the period </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">314</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">557</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> </table> <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td valign="top" width="4%" align="left">(1)</td> <td valign="top" align="left">Excess tax benefits received related to stock option exercises are presented as financing cash inflows. We currently do not receive a tax benefit related to the exercise of stock options due to our net operating losses.</td> </tr> </table> <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td valign="top" width="4%" align="left">(2)</td> <td valign="top" align="left">The intrinsic value of stock options exercised is the amount by which the market price of the stock on the date of exercise exceeded the market price of the stock on the date of grant.</td> </tr> </table> </div>

</biol:CashProceedsAlongWithFairValueDisclosuresRelatedToGrantsExercisesAndVestingOptionsTableTextBlock>

<biol:NoIndividualCountryOtherThanUnitedStatesRepresentsMoreThanTenPercentageOfNetRevenue contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" id="id_1838087_93B66F6A-F9D2-4337-99C4-95C751934132_1_0"> No individual country, other than the United States, represents more than 10% of total net revenue. </biol:NoIndividualCountryOtherThanUnitedStatesRepresentsMoreThanTenPercentageOfNetRevenue>

<biol:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOne contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" id="id_1838087_F5FACDCD-D74B-4383-8D73-8F77367ED3F7_1_0"> P3Y8M12D </biol:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOne>

<biol:SpecialStockDividendsDeclared contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" unitRef="pure" decimals="3" id="id_1838087_CF38A140-4253-41AE-9E72-55B77B0C0D93_1_1"> 0.005 </biol:SpecialStockDividendsDeclared>

<biol:ProductsAndServicesRevenue contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_A00DA052-212E-4E5F-A7B6-0262EF095DF3_1_0"> 14489000 </biol:ProductsAndServicesRevenue>

<biol:ShareBasedCompensationNetImpactOnEarningPerShareDiluted contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_1838087_053476C4-3EF5-4933-8AA5-88BFA09A7E6B_1_2"> -0.01 </biol:ShareBasedCompensationNetImpactOnEarningPerShareDiluted>

<biol:AmortizationOfDiscountsOnLinesOfCredit contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_4DB91CB0-1518-4BBC-9D34-97A2604088B3_1_5"> 18000 </biol:AmortizationOfDiscountsOnLinesOfCredit>

<biol:ShareBasedCompensationNetImpactOnEarningPerShareBasic contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_1838087_053476C4-3EF5-4933-8AA5-88BFA09A7E6B_1_1"> -0.01 </biol:ShareBasedCompensationNetImpactOnEarningPerShareBasic>

<biol:AccruedLiabilitiesAndDeferredRevenueTextBlock contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" id="id_1838087_98D19F78-1AEA-4C39-8B3A-BD08C62CE25D_1_0">

<div> NOTE 7 –ACCRUED LIABILITIES AND DEFERRED REVENUE Accrued liabilities are comprised of the following (in thousands): <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="76%" align="center"> <tr> <td width="68%"></td> <td valign="bottom" width="11%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="11%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">March 31, 2013</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">December 31, 2012</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Payroll and benefits </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,613</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,326</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr> <td valign="top"> Warranty accrual </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,755</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,699</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Sales tax </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">421</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">640</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr> <td valign="top"> Accrued professional services </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">650</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">502</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Accrued insurance premium </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">326</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">751</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr> <td valign="top"> Other </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">114</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">349</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Accrued liabilities </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,879</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,267</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> </tr> </table> Changes in the initial product warranty accrual, and the expenses incurred under our initial and extended warranties, for the three months ended March 31, 2013 and 2012 were as follows (in thousands): <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="76%" align="center"> <tr> <td width="82%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="6" align="center">Three Months Ended March 31,</td> <td valign="bottom"> </td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">2013</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">2012</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Initial warranty accrual, beginning balance </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,699</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,218</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr> <td valign="top"> Provision for estimated warranty cost </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">650</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">122</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Warranty expenditures </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(594</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(414</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> </tr> <tr> <td valign="top"> Initial warranty accrual, ending balance </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,755</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,926</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Total warranty accrual, long term </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right">— </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right">— </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> </tr> <tr> <td valign="top"> Total warranty accrual, current portion </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,755</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,926</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> </tr> </table> Deferred revenue is comprised of the following (in thousands): <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="76%" align="center"> <tr> <td width="68%"></td> <td valign="bottom" width="12%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="12%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">March 31, 2013</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">December 31, 2012</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Undelivered elements (training, installation and product and support services) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,623</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,723</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr> <td valign="top"> Extended warranty contracts </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,510</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,506</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Total deferred revenue </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,133</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,229</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> </tr> <tr> <td valign="top"> Less long-term amounts: </td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Extended warranty contracts </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(2</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(3</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> </tr> <tr> <td valign="top"> Total deferred revenue, long-term </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(2</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(3</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Total deferred revenue, current portion </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,131</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,226</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> </tr> </table> </div>

</biol:AccruedLiabilitiesAndDeferredRevenueTextBlock>

<biol:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsVestedInPeriodFairValue contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_643BC9AC-CC98-4735-8599-488FD13A80CB_1_4"> 314000 </biol:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsVestedInPeriodFairValue>

<biol:ConcentrationsTextBlock contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" id="id_1838087_5F9CB826-B035-4DBE-B0E0-BEB28E8B1B41_1_0">

<div> NOTE 11—CONCENTRATIONS Revenue from laser systems, the Company’s core product, which includes the iPlus, MD Turbo, and Epic, comprised 70% and 76% of total net revenues for the three months ended March 31, 2013 and 2012, respectively. Revenue from consumables and other comprised 11% and 12% of total net revenue for the same periods. Revenue from imaging systems comprised 7% and 1% of total net revenue for the same periods. Revenue from services comprised 11% and 11% of total net revenue for the same periods. Revenue from license fees and royalties comprised 1% and 0% of total net revenue for the same periods. No individual customer represented more than 10% of the Company’s revenue in the three months ended March 31, 2013 and 2012. The Company maintains its cash and cash equivalent accounts with established commercial banks. Such cash deposits periodically exceed the Federal Deposit Insurance Corporation insured limit. No individual customer represented more than 10% of the Company’s accounts receivable at March 31, 2013 and December 31, 2012. The Company currently purchases certain key components of its products from single suppliers. Although there are a limited number of manufacturers of these key components, management believes that other suppliers could provide similar key components on comparable terms. A change in suppliers, however, could cause delays in manufacturing and a possible loss of sales, which could adversely affect the Company’s results of operations. </div>

</biol:ConcentrationsTextBlock>

<biol:SalesToCustomersLocatedWithinUnitedStates contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" unitRef="pure" decimals="2" id="id_1838087_BC90D91D-EBDC-425C-B230-5506FF61F163_1_0"> 0.62 </biol:SalesToCustomersLocatedWithinUnitedStates>

<biol:NewAccountingStandardsNotYetAdoptedPolicyTextBlock contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" id="id_1838087_9F09A30D-F2DD-47C5-94F9-A269A37753CB_1_0">

<div> New Accounting Standards Not Yet Adopted In March 2013, the FASB issued guidance on a parent’s accounting for the cumulative translation adjustment upon derecognition of certain subsidiaries or groups of assets within a foreign entity or of an investment in a foreign entity. The revised guidance requires that the parent release any related cumulative translation adjustment into net income only if the sale or transfer results in the complete or substantially complete liquidation of the foreign entity in which the subsidiary or group of assets had resided. The guidance is effective prospectively for reporting periods beginning after December 15, 2013. Early adoption is permitted. Management believes that the adoption of this guidance will not have a material impact on the Company’s consolidated financial statements. </div>

</biol:NewAccountingStandardsNotYetAdoptedPolicyTextBlock>

<biol:SalesToCustomersLocatedOutsideOfUnitedStates contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" unitRef="pure" decimals="2" id="id_1838087_BC90D91D-EBDC-425C-B230-5506FF61F163_1_1"> 0.38 </biol:SalesToCustomersLocatedOutsideOfUnitedStates>

<biol:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredVestedWeightedAverageExercisePrice contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" unitRef="iso4217_USD_per_shares" xsi:nil="true" id="id_1838087_71909E03-642B-4EB8-B21D-D1B644B7C37C_5001_8"/>

<biol:ExciseTax contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_A00DA052-212E-4E5F-A7B6-0262EF095DF3_1_9"> 107000 </biol:ExciseTax>

<us-gaap:SalesRevenueNet contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0_501891x498006" unitRef="iso4217_USD" decimals="-3" id="id_1838087_44E8E51B-6213-4CD0-B21D-5299654E2CA6_1001_0"> 9048000 </us-gaap:SalesRevenueNet>

<us-gaap:SalesRevenueNet contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0_501891x505266" unitRef="iso4217_USD" decimals="-3" id="id_1838087_44E8E51B-6213-4CD0-B21D-5299654E2CA6_2001_1"> 5549000 </us-gaap:SalesRevenueNet>

<us-gaap:InterestExpenseBorrowings contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0_503845x508355" unitRef="iso4217_USD" decimals="0" id="id_1838087_65E0AFDA-8528-43B0-8417-3ED2204F154C_1001_6"> 84000 </us-gaap:InterestExpenseBorrowings>

<us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0_504296x510320" unitRef="iso4217_USD" decimals="-3" id="id_1838087_D3F8CF0E-ACC2-4285-89F9-B2C540B9CB0B_1001_2"> 115000 </us-gaap:AllocatedShareBasedCompensationExpense>

<us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0_504296x549651" unitRef="iso4217_USD" decimals="-3" id="id_1838087_D3F8CF0E-ACC2-4285-89F9-B2C540B9CB0B_2001_1"> 139000 </us-gaap:AllocatedShareBasedCompensationExpense>

<us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0_504296x555087" unitRef="iso4217_USD" decimals="-3" id="id_1838087_D3F8CF0E-ACC2-4285-89F9-B2C540B9CB0B_3001_0"> 80000 </us-gaap:AllocatedShareBasedCompensationExpense>

<us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0_504296x595048" unitRef="iso4217_USD" decimals="-3" id="id_1838087_D3F8CF0E-ACC2-4285-89F9-B2C540B9CB0B_4001_3"> 34000 </us-gaap:AllocatedShareBasedCompensationExpense>

<us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0_504957x513639_512758x501065" id="id_1838087_F82351F1-BC71-4D46-B742-3046E734FE2D_4001_2"> P4Y </us-gaap:FiniteLivedIntangibleAssetUsefulLife>

<us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0_504957x513639_512758x502477" id="id_1838087_F82351F1-BC71-4D46-B742-3046E734FE2D_4003_2"> P4Y </us-gaap:FiniteLivedIntangibleAssetUsefulLife>

<us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0_504957x514053_512758x501065" id="id_1838087_F82351F1-BC71-4D46-B742-3046E734FE2D_5001_3"> P10Y </us-gaap:FiniteLivedIntangibleAssetUsefulLife>

<us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0_504957x514053_512758x502477" id="id_1838087_F82351F1-BC71-4D46-B742-3046E734FE2D_5003_3"> P6Y </us-gaap:FiniteLivedIntangibleAssetUsefulLife>

<biol:NumberOfWarrantsExercised contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0_507199x551171" unitRef="shares" decimals="INF" id="id_1838087_F422CB74-A961-4DA9-9D0E-AC5F6E7C2C04_1002_2"> 80000 </biol:NumberOfWarrantsExercised>

<us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0_507611x652001" unitRef="pure" decimals="4" id="id_1838087_65E0AFDA-8528-43B0-8417-3ED2204F154C_2001_5"> 0.0025 </us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage>

<us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0_507611x652129" unitRef="pure" decimals="4" id="id_1838087_65E0AFDA-8528-43B0-8417-3ED2204F154C_3001_4"> 0.0025 </us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage>

<biol:ResearchAndDevelopmentFederalTaxCreditCarryforwardsExpirationDateYear contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0_508681x532681" id="id_1838087_4CD013EE-034E-4E26-A7F7-2E9282E137A7_1001_5"> 2018 </biol:ResearchAndDevelopmentFederalTaxCreditCarryforwardsExpirationDateYear>

<biol:PercentageOfNetRevenue contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0_510496x549700" unitRef="pure" decimals="2" id="id_1838087_A8148830-E319-43CA-B949-14538FB3D99F_1001_3"> 0.11 </biol:PercentageOfNetRevenue>

<biol:PercentageOfNetRevenue contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0_510496x652157" unitRef="pure" decimals="2" id="id_1838087_A8148830-E319-43CA-B949-14538FB3D99F_2001_2"> 0.07 </biol:PercentageOfNetRevenue>

<biol:PercentageOfNetRevenue contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0_510496x693138" unitRef="pure" decimals="2" id="id_1838087_A8148830-E319-43CA-B949-14538FB3D99F_3001_4"> 0.01 </biol:PercentageOfNetRevenue>

<biol:PercentageOfNetRevenue contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0_510496x694007" unitRef="pure" decimals="2" id="id_1838087_A8148830-E319-43CA-B949-14538FB3D99F_4001_1"> 0.11 </biol:PercentageOfNetRevenue>

<biol:PercentageOfNetRevenue contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0_510496x703662" unitRef="pure" decimals="2" id="id_1838087_A8148830-E319-43CA-B949-14538FB3D99F_5001_0"> 0.70 </biol:PercentageOfNetRevenue>

<us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0_512758x512398" id="id_1838087_F82351F1-BC71-4D46-B742-3046E734FE2D_3002_1"> P6Y </us-gaap:FiniteLivedIntangibleAssetUsefulLife>

<us-gaap:IncomeTaxExpenseBenefit contextRef="eol_PE753-----1310-Q0003_STD_90_20130331_0_623150x532706" unitRef="iso4217_USD" decimals="0" id="id_1838087_F0A3794A-0445-411C-BF60-DBDBBD5B085B_1001_0"> 158000 </us-gaap:IncomeTaxExpenseBenefit>

<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE753-----1310-Q0003_STD_91_20120331_0" unitRef="pure" decimals="4" id="id_1838087_F5FACDCD-D74B-4383-8D73-8F77367ED3F7_2_3"> 0.0093 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>

<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="eol_PE753-----1310-Q0003_STD_91_20120331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_643BC9AC-CC98-4735-8599-488FD13A80CB_2_2"> 11000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>

<us-gaap:OperatingIncomeLoss contextRef="eol_PE753-----1310-Q0003_STD_91_20120331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_A00DA052-212E-4E5F-A7B6-0262EF095DF3_2_11"> -1622000 </us-gaap:OperatingIncomeLoss>

<us-gaap:OtherNoncashIncomeExpense contextRef="eol_PE753-----1310-Q0003_STD_91_20120331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_4DB91CB0-1518-4BBC-9D34-97A2604088B3_2_9"> -62000 </us-gaap:OtherNoncashIncomeExpense>

<us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions contextRef="eol_PE753-----1310-Q0003_STD_91_20120331_0" unitRef="iso4217_USD" xsi:nil="true" id="id_1838087_643BC9AC-CC98-4735-8599-488FD13A80CB_2_1"/>

<us-gaap:StandardProductWarrantyAccrualWarrantiesIssued contextRef="eol_PE753-----1310-Q0003_STD_91_20120331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_EC213DCE-C2D3-4357-95A0-1D70B1065A3D_2_1"> 122000 </us-gaap:StandardProductWarrantyAccrualWarrantiesIssued>

<us-gaap:ComprehensiveIncomeNetOfTax contextRef="eol_PE753-----1310-Q0003_STD_91_20120331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_A00DA052-212E-4E5F-A7B6-0262EF095DF3_2_20"> -1609000 </us-gaap:ComprehensiveIncomeNetOfTax>

<us-gaap:DepreciationDepletionAndAmortization contextRef="eol_PE753-----1310-Q0003_STD_91_20120331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_4DB91CB0-1518-4BBC-9D34-97A2604088B3_2_3"> 125000 </us-gaap:DepreciationDepletionAndAmortization>

<us-gaap:ShareBasedCompensation contextRef="eol_PE753-----1310-Q0003_STD_91_20120331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_4DB91CB0-1518-4BBC-9D34-97A2604088B3_2_7"> 583000 </us-gaap:ShareBasedCompensation>

<us-gaap:EarningsPerShareDiluted contextRef="eol_PE753-----1310-Q0003_STD_91_20120331_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_1838087_A00DA052-212E-4E5F-A7B6-0262EF095DF3_2_23"> -0.05 </us-gaap:EarningsPerShareDiluted>

<us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="eol_PE753-----1310-Q0003_STD_91_20120331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_4DB91CB0-1518-4BBC-9D34-97A2604088B3_2_16"> -957000 </us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>

<us-gaap:ProvisionForDoubtfulAccounts contextRef="eol_PE753-----1310-Q0003_STD_91_20120331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_4DB91CB0-1518-4BBC-9D34-97A2604088B3_2_4"> 16000 </us-gaap:ProvisionForDoubtfulAccounts>

<us-gaap:ProceedsFromStockOptionsExercised contextRef="eol_PE753-----1310-Q0003_STD_91_20120331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_4DB91CB0-1518-4BBC-9D34-97A2604088B3_2_26"> 277000 </us-gaap:ProceedsFromStockOptionsExercised>

<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="eol_PE753-----1310-Q0003_STD_91_20120331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_4DB91CB0-1518-4BBC-9D34-97A2604088B3_2_18"> -593000 </us-gaap:NetCashProvidedByUsedInOperatingActivities>

<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="eol_PE753-----1310-Q0003_STD_91_20120331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_4DB91CB0-1518-4BBC-9D34-97A2604088B3_2_22"> -266000 </us-gaap:NetCashProvidedByUsedInInvestingActivities>

<us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="eol_PE753-----1310-Q0003_STD_91_20120331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_4DB91CB0-1518-4BBC-9D34-97A2604088B3_2_17"> -111000 </us-gaap:IncreaseDecreaseInDeferredRevenue>

<us-gaap:IncreaseDecreaseInCustomerDeposits contextRef="eol_PE753-----1310-Q0003_STD_91_20120331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_4DB91CB0-1518-4BBC-9D34-97A2604088B3_2_15"> -145000 </us-gaap:IncreaseDecreaseInCustomerDeposits>

<us-gaap:ProductWarrantyExpense contextRef="eol_PE753-----1310-Q0003_STD_91_20120331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_EC213DCE-C2D3-4357-95A0-1D70B1065A3D_2_2"> 414000 </us-gaap:ProductWarrantyExpense>

<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="eol_PE753-----1310-Q0003_STD_91_20120331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_4DB91CB0-1518-4BBC-9D34-97A2604088B3_2_20"> 266000 </us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>

<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="eol_PE753-----1310-Q0003_STD_91_20120331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_4DB91CB0-1518-4BBC-9D34-97A2604088B3_2_29"> -535000 </us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>

<us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE753-----1310-Q0003_STD_91_20120331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_A00DA052-212E-4E5F-A7B6-0262EF095DF3_2_7"> 2211000 </us-gaap:GeneralAndAdministrativeExpense>

<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="eol_PE753-----1310-Q0003_STD_91_20120331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_4DB91CB0-1518-4BBC-9D34-97A2604088B3_2_14"> -606000 </us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>

<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="eol_PE753-----1310-Q0003_STD_91_20120331_0" unitRef="shares" decimals="-3" id="id_1838087_A00DA052-212E-4E5F-A7B6-0262EF095DF3_2_26"> 31358000 </us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>

<us-gaap:SalesRevenueNet contextRef="eol_PE753-----1310-Q0003_STD_91_20120331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_A00DA052-212E-4E5F-A7B6-0262EF095DF3_2_2"> 12320000 </us-gaap:SalesRevenueNet>

<us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="eol_PE753-----1310-Q0003_STD_91_20120331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_4DB91CB0-1518-4BBC-9D34-97A2604088B3_2_12"> 100000 </us-gaap:IncreaseDecreaseInAccountsReceivable>

<us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="eol_PE753-----1310-Q0003_STD_91_20120331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_A00DA052-212E-4E5F-A7B6-0262EF095DF3_2_19"> 63000 </us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>

<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="eol_PE753-----1310-Q0003_STD_91_20120331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_A00DA052-212E-4E5F-A7B6-0262EF095DF3_2_15"> -1643000 </us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>

<us-gaap:SellingAndMarketingExpense contextRef="eol_PE753-----1310-Q0003_STD_91_20120331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_A00DA052-212E-4E5F-A7B6-0262EF095DF3_2_6"> 4028000 </us-gaap:SellingAndMarketingExpense>

<us-gaap:EarningsPerShareBasic contextRef="eol_PE753-----1310-Q0003_STD_91_20120331_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_1838087_A00DA052-212E-4E5F-A7B6-0262EF095DF3_2_22"> -0.05 </us-gaap:EarningsPerShareBasic>

<us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE753-----1310-Q0003_STD_91_20120331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_A00DA052-212E-4E5F-A7B6-0262EF095DF3_2_8"> 1190000 </us-gaap:ResearchAndDevelopmentExpense>

<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="eol_PE753-----1310-Q0003_STD_91_20120331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_4DB91CB0-1518-4BBC-9D34-97A2604088B3_2_27"> 277000 </us-gaap:NetCashProvidedByUsedInFinancingActivities>

<us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease contextRef="eol_PE753-----1310-Q0003_STD_91_20120331_0" unitRef="iso4217_USD" decimals="0" id="id_1838087_F5411727-EC2E-4299-AACA-CD650501D310_2_0"> 1000 </us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease>

<us-gaap:OperatingExpenses contextRef="eol_PE753-----1310-Q0003_STD_91_20120331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_A00DA052-212E-4E5F-A7B6-0262EF095DF3_2_10"> 7429000 </us-gaap:OperatingExpenses>

<us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="eol_PE753-----1310-Q0003_STD_91_20120331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_A00DA052-212E-4E5F-A7B6-0262EF095DF3_2_13"> -4000 </us-gaap:InterestIncomeExpenseNonoperatingNet>

<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE753-----1310-Q0003_STD_91_20120331_0" unitRef="pure" decimals="4" id="id_1838087_F5FACDCD-D74B-4383-8D73-8F77367ED3F7_2_1"> 1.0200 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>

<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="eol_PE753-----1310-Q0003_STD_91_20120331_0" unitRef="shares" decimals="-3" id="id_1838087_A00DA052-212E-4E5F-A7B6-0262EF095DF3_2_25"> 31358000 </us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>

<us-gaap:IncreaseDecreaseInInventories contextRef="eol_PE753-----1310-Q0003_STD_91_20120331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_4DB91CB0-1518-4BBC-9D34-97A2604088B3_2_13"> -975000 </us-gaap:IncreaseDecreaseInInventories>

<us-gaap:CostOfGoodsSold contextRef="eol_PE753-----1310-Q0003_STD_91_20120331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_A00DA052-212E-4E5F-A7B6-0262EF095DF3_2_3"> 6513000 </us-gaap:CostOfGoodsSold>

<us-gaap:IncomeTaxesPaidNet contextRef="eol_PE753-----1310-Q0003_STD_91_20120331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_4DB91CB0-1518-4BBC-9D34-97A2604088B3_2_34"> 21000 </us-gaap:IncomeTaxesPaidNet>

<us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE753-----1310-Q0003_STD_91_20120331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_053476C4-3EF5-4933-8AA5-88BFA09A7E6B_2_0"> 583000 </us-gaap:AllocatedShareBasedCompensationExpense>

<us-gaap:GrossProfit contextRef="eol_PE753-----1310-Q0003_STD_91_20120331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_A00DA052-212E-4E5F-A7B6-0262EF095DF3_2_4"> 5807000 </us-gaap:GrossProfit>

<us-gaap:InterestPaid contextRef="eol_PE753-----1310-Q0003_STD_91_20120331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_4DB91CB0-1518-4BBC-9D34-97A2604088B3_2_33"> 3000 </us-gaap:InterestPaid>

<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE753-----1310-Q0003_STD_91_20120331_0" unitRef="shares" decimals="INF" id="id_1838087_9F5FAA7E-3B9D-460F-9024-6FC808FA9242_2_0"> 4514000 </us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>

<us-gaap:NetIncomeLoss contextRef="eol_PE753-----1310-Q0003_STD_91_20120331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_A00DA052-212E-4E5F-A7B6-0262EF095DF3_2_17"> -1672000 </us-gaap:NetIncomeLoss>

<us-gaap:NonoperatingIncomeExpense contextRef="eol_PE753-----1310-Q0003_STD_91_20120331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_A00DA052-212E-4E5F-A7B6-0262EF095DF3_2_14"> -21000 </us-gaap:NonoperatingIncomeExpense>

<us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="eol_PE753-----1310-Q0003_STD_91_20120331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_A00DA052-212E-4E5F-A7B6-0262EF095DF3_2_12"> -17000 </us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>

<us-gaap:IncomeTaxExpenseBenefit contextRef="eol_PE753-----1310-Q0003_STD_91_20120331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_A00DA052-212E-4E5F-A7B6-0262EF095DF3_2_16"> 29000 </us-gaap:IncomeTaxExpenseBenefit>

<us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="eol_PE753-----1310-Q0003_STD_91_20120331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_4DB91CB0-1518-4BBC-9D34-97A2604088B3_2_28"> 47000 </us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>

<us-gaap:AmortizationOfIntangibleAssets contextRef="eol_PE753-----1310-Q0003_STD_91_20120331_0" unitRef="iso4217_USD" decimals="0" id="id_1838087_5C3FF8A6-54CB-4B64-B6AC-506288609EB6_2_0"> 33000 </us-gaap:AmortizationOfIntangibleAssets>

<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="eol_PE753-----1310-Q0003_STD_91_20120331_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_1838087_643BC9AC-CC98-4735-8599-488FD13A80CB_2_3"> 1.99 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>

<biol:EntityWideRevenueMajorCustomerNumber contextRef="eol_PE753-----1310-Q0003_STD_91_20120331_0" unitRef="Customer" decimals="INF" id="id_1838087_EACBDC32-9092-47B0-AA70-97988FB2993A_2_0"> 0 </biol:EntityWideRevenueMajorCustomerNumber>

<biol:OtherEquityInstrumentsCompensation contextRef="eol_PE753-----1310-Q0003_STD_91_20120331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_4DB91CB0-1518-4BBC-9D34-97A2604088B3_2_8"> 25000 </biol:OtherEquityInstrumentsCompensation>

<biol:LicenseFeesAndRoyaltyRevenue contextRef="eol_PE753-----1310-Q0003_STD_91_20120331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_A00DA052-212E-4E5F-A7B6-0262EF095DF3_2_1"> 8000 </biol:LicenseFeesAndRoyaltyRevenue>

<biol:DepreciationDepletionAndAmortizationOfPropertyPlantAndEquipment contextRef="eol_PE753-----1310-Q0003_STD_91_20120331_0" unitRef="iso4217_USD" decimals="0" id="id_1838087_0AB21D10-75AF-44BE-B0CE-62F7741FC060_2_0"> 92000 </biol:DepreciationDepletionAndAmortizationOfPropertyPlantAndEquipment>

<biol:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividend contextRef="eol_PE753-----1310-Q0003_STD_91_20120331_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_1838087_F5FACDCD-D74B-4383-8D73-8F77367ED3F7_2_2"> 0.00 </biol:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividend>

<biol:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOne contextRef="eol_PE753-----1310-Q0003_STD_91_20120331_0" id="id_1838087_F5FACDCD-D74B-4383-8D73-8F77367ED3F7_2_0"> P4Y1M6D </biol:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOne>

<biol:ProductsAndServicesRevenue contextRef="eol_PE753-----1310-Q0003_STD_91_20120331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_A00DA052-212E-4E5F-A7B6-0262EF095DF3_2_0"> 12312000 </biol:ProductsAndServicesRevenue>

<biol:ShareBasedCompensationNetImpactOnEarningPerShareDiluted contextRef="eol_PE753-----1310-Q0003_STD_91_20120331_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_1838087_053476C4-3EF5-4933-8AA5-88BFA09A7E6B_2_2"> -0.01 </biol:ShareBasedCompensationNetImpactOnEarningPerShareDiluted>

<biol:ShareBasedCompensationNetImpactOnEarningPerShareBasic contextRef="eol_PE753-----1310-Q0003_STD_91_20120331_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_1838087_053476C4-3EF5-4933-8AA5-88BFA09A7E6B_2_1"> -0.01 </biol:ShareBasedCompensationNetImpactOnEarningPerShareBasic>

<biol:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsVestedInPeriodFairValue contextRef="eol_PE753-----1310-Q0003_STD_91_20120331_0" unitRef="iso4217_USD" decimals="-3" id="id_1838087_643BC9AC-CC98-4735-8599-488FD13A80CB_2_4"> 557000 </biol:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsVestedInPeriodFairValue>

<biol:SalesToCustomersLocatedWithinUnitedStates contextRef="eol_PE753-----1310-Q0003_STD_91_20120331_0" unitRef="pure" decimals="2" id="id_1838087_BC90D91D-EBDC-425C-B230-5506FF61F163_2_0"> 0.68 </biol:SalesToCustomersLocatedWithinUnitedStates>

<biol:SalesToCustomersLocatedOutsideOfUnitedStates contextRef="eol_PE753-----1310-Q0003_STD_91_20120331_0" unitRef="pure" decimals="2" id="id_1838087_BC90D91D-EBDC-425C-B230-5506FF61F163_2_1"> 0.32 </biol:SalesToCustomersLocatedOutsideOfUnitedStates>

<us-gaap:SalesRevenueNet contextRef="eol_PE753-----1310-Q0003_STD_91_20120331_0_501891x498006" unitRef="iso4217_USD" decimals="-3" id="id_1838087_44E8E51B-6213-4CD0-B21D-5299654E2CA6_1002_0"> 8364000 </us-gaap:SalesRevenueNet>

<us-gaap:SalesRevenueNet contextRef="eol_PE753-----1310-Q0003_STD_91_20120331_0_501891x505266" unitRef="iso4217_USD" decimals="-3" id="id_1838087_44E8E51B-6213-4CD0-B21D-5299654E2CA6_2002_1"> 3956000 </us-gaap:SalesRevenueNet>

<us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE753-----1310-Q0003_STD_91_20120331_0_504296x510320" unitRef="iso4217_USD" decimals="-3" id="id_1838087_D3F8CF0E-ACC2-4285-89F9-B2C540B9CB0B_1002_2"> 358000 </us-gaap:AllocatedShareBasedCompensationExpense>

<us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE753-----1310-Q0003_STD_91_20120331_0_504296x549651" unitRef="iso4217_USD" decimals="-3" id="id_1838087_D3F8CF0E-ACC2-4285-89F9-B2C540B9CB0B_2002_1"> 121000 </us-gaap:AllocatedShareBasedCompensationExpense>

<us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE753-----1310-Q0003_STD_91_20120331_0_504296x555087" unitRef="iso4217_USD" decimals="-3" id="id_1838087_D3F8CF0E-ACC2-4285-89F9-B2C540B9CB0B_3002_0"> 58000 </us-gaap:AllocatedShareBasedCompensationExpense>

<us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE753-----1310-Q0003_STD_91_20120331_0_504296x595048" unitRef="iso4217_USD" decimals="-3" id="id_1838087_D3F8CF0E-ACC2-4285-89F9-B2C540B9CB0B_4002_3"> 46000 </us-gaap:AllocatedShareBasedCompensationExpense>

<biol:PercentageOfNetRevenue contextRef="eol_PE753-----1310-Q0003_STD_91_20120331_0_510496x549700" unitRef="pure" decimals="2" id="id_1838087_A8148830-E319-43CA-B949-14538FB3D99F_1002_3"> 0.11 </biol:PercentageOfNetRevenue>

<biol:PercentageOfNetRevenue contextRef="eol_PE753-----1310-Q0003_STD_91_20120331_0_510496x652157" unitRef="pure" decimals="2" id="id_1838087_A8148830-E319-43CA-B949-14538FB3D99F_2002_2"> 0.01 </biol:PercentageOfNetRevenue>

<biol:PercentageOfNetRevenue contextRef="eol_PE753-----1310-Q0003_STD_91_20120331_0_510496x693138" unitRef="pure" decimals="2" id="id_1838087_A8148830-E319-43CA-B949-14538FB3D99F_3002_4"> 0.00 </biol:PercentageOfNetRevenue>

<biol:PercentageOfNetRevenue contextRef="eol_PE753-----1310-Q0003_STD_91_20120331_0_510496x694007" unitRef="pure" decimals="2" id="id_1838087_A8148830-E319-43CA-B949-14538FB3D99F_4002_1"> 0.12 </biol:PercentageOfNetRevenue>

<biol:PercentageOfNetRevenue contextRef="eol_PE753-----1310-Q0003_STD_91_20120331_0_510496x703662" unitRef="pure" decimals="2" id="id_1838087_A8148830-E319-43CA-B949-14538FB3D99F_5002_0"> 0.76 </biol:PercentageOfNetRevenue>

<biol:SpecialStockDividendsIntended contextRef="eol_PE753-----1310-Q0003_STD_92_20131231_0_506663x511390" unitRef="pure" decimals="2" id="id_1838087_5ABC2DBA-170C-4F08-8CF6-A399E42EBF42_1_0"> 0.02 </biol:SpecialStockDividendsIntended>

<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis"> us-gaap:SubsequentEventMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis"> biol:LaserSystemsMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis"> biol:ConsumableAndOtherMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis"> biol:LicenseFeesAndRoyaltiesMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis"> biol:ImagingSystemMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis"> biol:ServiceMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis"> biol:EngineeringAndDevelopmentMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis"> biol:CostOfRevenueMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis"> biol:SalesAndMarketingMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis"> us-gaap:GeneralAndAdministrativeExpenseMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis"> us-gaap:SegmentGeographicalGroupsOfCountriesGroupTwoMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis"> us-gaap:SegmentGeographicalGroupsOfCountriesGroupOneMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="biol:IncomeTaxAxis"> biol:ExpectedFutureTaxRateMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis"> us-gaap:TrademarksMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis"> biol:LaserSystemsMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis"> biol:ConsumableAndOtherMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis"> biol:LicenseFeesAndRoyaltiesMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis"> biol:ImagingSystemMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis"> biol:ServiceMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis"> biol:FederalMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis"> biol:DomesticRevolverCreditFacilityMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis"> biol:ExImRevolverMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis"> biol:ComericaBankMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis"> us-gaap:OtherIntangibleAssetsMember </xbrldi:explicitMember>

<xbrldi:explicitMember dimension="us-gaap:RangeAxis"> us-gaap:MaximumMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis"> us-gaap:PatentsMember </xbrldi:explicitMember>

<xbrldi:explicitMember dimension="us-gaap:RangeAxis"> us-gaap:MaximumMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis"> us-gaap:OtherIntangibleAssetsMember </xbrldi:explicitMember>

<xbrldi:explicitMember dimension="us-gaap:RangeAxis"> us-gaap:MinimumMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis"> us-gaap:PatentsMember </xbrldi:explicitMember>

<xbrldi:explicitMember dimension="us-gaap:RangeAxis"> us-gaap:MinimumMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis"> biol:CostOfRevenueMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis"> biol:SalesAndMarketingMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis"> us-gaap:LineOfCreditMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis"> us-gaap:SegmentGeographicalGroupsOfCountriesGroupTwoMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis"> us-gaap:SegmentGeographicalGroupsOfCountriesGroupOneMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis"> biol:DomesticRevolverCreditFacilityMember </xbrldi:explicitMember>

<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis"> us-gaap:SubsequentEventMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis"> biol:ExImRevolverMember </xbrldi:explicitMember>

<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis"> us-gaap:SubsequentEventMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:NewContractAxis"> biol:AffiliationAgreementMember </xbrldi:explicitMember>

<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis"> us-gaap:SubsequentEventMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis"> biol:WarrantTwoMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis"> us-gaap:TrademarksMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis"> us-gaap:OtherIntangibleAssetsMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis"> us-gaap:PatentsMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis"> us-gaap:ComputerEquipmentMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis"> us-gaap:LandMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis"> us-gaap:BuildingMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis"> us-gaap:ConstructionInProgressMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis"> us-gaap:FurnitureAndFixturesMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis"> us-gaap:LeaseholdImprovementsMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis"> biol:DomesticRevolverCreditFacilityMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis"> biol:ExImRevolverMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis"> biol:ComericaBankMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis"> biol:InternationalMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

</entity>

</period>

</context>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis"> us-gaap:TrademarksMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis"> us-gaap:OtherIntangibleAssetsMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis"> us-gaap:PatentsMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis"> us-gaap:ComputerEquipmentMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis"> us-gaap:LandMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis"> us-gaap:BuildingMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis"> us-gaap:ConstructionInProgressMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis"> us-gaap:FurnitureAndFixturesMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis"> us-gaap:LeaseholdImprovementsMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis"> biol:FederalMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis"> biol:StateMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> biol:TwoThousandTwoStockIncentivePlanMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis"> biol:DomesticRevolverCreditFacilityMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis"> biol:ExImRevolverMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis"> biol:ComericaBankMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis"> biol:InternationalMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

</entity>

</period>

</context>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:NewContractAxis"> biol:AffiliationAgreementMember </xbrldi:explicitMember>

<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis"> us-gaap:SubsequentEventMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis"> biol:WarrantTwoMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> biol:BonusShareMember </xbrldi:explicitMember>

<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis"> biol:WarrantTwoMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis"> biol:WarrantTwoMember </xbrldi:explicitMember>

<xbrldi:explicitMember dimension="us-gaap:RangeAxis"> us-gaap:MaximumMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> biol:BonusShareMember </xbrldi:explicitMember>

<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis"> biol:WarrantTwoMember </xbrldi:explicitMember>

<xbrldi:explicitMember dimension="us-gaap:RangeAxis"> us-gaap:MaximumMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis"> biol:WarrantTwoMember </xbrldi:explicitMember>

<xbrldi:explicitMember dimension="us-gaap:RangeAxis"> us-gaap:MinimumMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis"> biol:DomesticRevolverCreditFacilityMember </xbrldi:explicitMember>

<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis"> us-gaap:SubsequentEventMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis"> biol:ExImRevolverMember </xbrldi:explicitMember>

<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis"> us-gaap:SubsequentEventMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis"> us-gaap:SubsequentEventMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

</entity>

</period>

</context>

<measure> shares </measure>

</unit>

</unit>

</unit>

</unitNumerator>

<measure> shares </measure>

</unitDenominator>

</divide>

</unit>

</unitNumerator>

</unitDenominator>

</divide>

</unit>

</unitNumerator>

</unitDenominator>

</divide>

</unit>

</unitNumerator>

<measure> biol:Right </measure>

</unitDenominator>

</divide>

</unit>

<measure> biol:Customer </measure>

</unit>

<measure> biol:Segment </measure>

</unit>

<measure> biol:Agreement </measure>

</unit>

<xbrll:footnoteLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">

<xbrll:loc xlink:href="#id_1838087_643BC9AC-CC98-4735-8599-488FD13A80CB_1_1" xlink:label="id_1838087_643BC9AC-CC98-4735-8599-488FD13A80CB_1_1" xlink:type="locator"/>

<xbrll:loc xlink:href="#id_1838087_643BC9AC-CC98-4735-8599-488FD13A80CB_1_2" xlink:label="id_1838087_643BC9AC-CC98-4735-8599-488FD13A80CB_1_2" xlink:type="locator"/>

<xbrll:loc xlink:href="#id_1838087_643BC9AC-CC98-4735-8599-488FD13A80CB_2_1" xlink:label="id_1838087_643BC9AC-CC98-4735-8599-488FD13A80CB_2_1" xlink:type="locator"/>

<xbrll:loc xlink:href="#id_1838087_643BC9AC-CC98-4735-8599-488FD13A80CB_2_2" xlink:label="id_1838087_643BC9AC-CC98-4735-8599-488FD13A80CB_2_2" xlink:type="locator"/>

<xbrll:loc xlink:href="#id_1838087_A50D0922-0FC2-4C71-A1A6-6ADC46F3675C_1001_2" xlink:label="id_1838087_A50D0922-0FC2-4C71-A1A6-6ADC46F3675C_1001_2" xlink:type="locator"/>

<xbrll:loc xlink:href="#id_1838087_A50D0922-0FC2-4C71-A1A6-6ADC46F3675C_1001_3" xlink:label="id_1838087_A50D0922-0FC2-4C71-A1A6-6ADC46F3675C_1001_3" xlink:type="locator"/>

<xbrll:footnote xlink:label="footnote_147060132" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"> The intrinsic value of stock options exercised is the amount by which the market price of the stock on the date of exercise exceeded the market price of the stock on the date of grant. </xbrll:footnote>

<xbrll:footnote xlink:label="footnote_147060137" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"> The intrinsic value calculation does not include negative values. This can occur when the fair market value on the reporting date is less than the exercise price of the grant. </xbrll:footnote>

<xbrll:footnote xlink:label="footnote_147060142" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"> Excess tax benefits received related to stock option exercises are presented as financing cash inflows. We currently do not receive a tax benefit related to the exercise of stock options due to our net operating losses. </xbrll:footnote>

<xbrll:footnoteArc xlink:from="id_1838087_643BC9AC-CC98-4735-8599-488FD13A80CB_1_1" xlink:to="footnote_147060142" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>

<xbrll:footnoteArc xlink:from="id_1838087_643BC9AC-CC98-4735-8599-488FD13A80CB_1_2" xlink:to="footnote_147060132" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>

<xbrll:footnoteArc xlink:from="id_1838087_643BC9AC-CC98-4735-8599-488FD13A80CB_2_1" xlink:to="footnote_147060142" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>

<xbrll:footnoteArc xlink:from="id_1838087_643BC9AC-CC98-4735-8599-488FD13A80CB_2_2" xlink:to="footnote_147060132" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>

<xbrll:footnoteArc xlink:from="id_1838087_A50D0922-0FC2-4C71-A1A6-6ADC46F3675C_1001_2" xlink:to="footnote_147060137" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>

<xbrll:footnoteArc xlink:from="id_1838087_A50D0922-0FC2-4C71-A1A6-6ADC46F3675C_1001_3" xlink:to="footnote_147060137" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>

</xbrll:footnoteLink>

</xbrl>

↑Top

Filing Submission 0001193125-13-214464 – Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Biolase, Inc – ‘10-Q’ for 3/31/13 – ‘EX-101.INS’

On: Friday, 5/10/13, at 4:58pm ET · For: 3/31/13 · Accession #: 1193125-13-214464 · File #: 0-19627

Previous ‘10-Q’: ‘10-Q’ on 11/9/12 for 9/30/12 · Next: ‘10-Q’ on 8/9/13 for 6/30/13 · Latest: ‘10-Q’ on 11/9/23 for 9/30/23

Quarterly Report — Form 10-Q — Sect. 13 / 15(d) – SEA’34Filing Table of Contents

‘EX-101.INS’ — XBRL Instance — biol-20130331

This Exhibit is an XBRL XML File.

Quarterly Report — Form 10-Q — Sect. 13 / 15(d) – SEA’34
Filing Table of Contents